



UNIVERSITY OF HELSINKI



<https://helda.helsinki.fi>

Helda

Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy

Ding, Yaping

Wiley-VCH Verlag

2019-01

Ding, Y, Li, W, Zhang, F, Liu, Z, Ezazi, N Z, Liu, D & Santos, H A 2019, 'Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy', *Advanced Functional Materials*, vol. 29, no. 2, 1802852. <https://doi.org/10.1002/adfm.201802852>

<http://hdl.handle.net/10138/327321>

10.1002/adfm.201802852

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Advanced Functional Materials

Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy --Manuscript Draft--

Manuscript Number:	adfm.201802852R3
Full Title:	Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer Therapy
Article Type:	Invited Review
Section/Category:	
Keywords:	Electrospinning; drug delivery system; tissue engineering; cancer therapy; Biomedical applications
Corresponding Author:	Helder Santos, D.Sc. (Chem. Eng.) University of Helsinki Helsinki, Helsinki FINLAND
Additional Information:	
Question	Response
Please submit a plain text version of your cover letter here.	<p>Dr. Jos Lenders Editor Advanced Functional Materials</p> <p>Dear Dr. Jos Lenders,</p> <p>Thank you very much for the second consideration on our manuscript and thank you for sending us the new referee's comments on our review.</p> <p>The comments from the three new reviewers are very valuable and highly helpful in improving our manuscript.</p> <p>A revised version of our manuscript addressing all the comments of the referees is provided. All the changes are clearly marked and highlighted in the text in yellow in the supplementary revised file.</p> <p>Another copy of the revised manuscript without marks is also provided as the main yrct.</p> <p>All the permissions for figures adapted from the literature have been uploaded as separated files.</p> <p>In the response letter, we have replied point-by-point to all of the reviewer's comments.</p> <p>I look forward to your positive response soon. Thank you very much in advanced for your kind consideration!</p> <p>Yours Sincerely, Hélder Santos</p> <hr/> <p>Dr. Hélder A. Santos, D.Sc. (Chem. Eng.), Associate Professor, Head of Division Head of the Division of Pharmaceutical Chemistry and Technology Head of the Nanomedicines and Biomedical Engineering Group Head of Preclinical Drug Formulation and Analysis Group</p>

	<p>Drug Research Program, Faculty of Pharmacy, University of Helsinki, Finland; & Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Finland</p> <p>@: helder.santos@helsinki.fi, http://www.helsinki.fi/~hsantos/ https://scholar.google.com/citations?hl=en-EN&user=K3Pj_gwAAAAAJ</p>
Do you or any of your co-authors have a conflict of interest to declare?	No. The authors declare no conflict of interest.
Corresponding Author Secondary Information:	
Corresponding Author's Institution:	University of Helsinki
Corresponding Author's Secondary Institution:	
First Author:	Yapin Ding
First Author Secondary Information:	
Order of Authors:	Yapin Ding
	Wei Li
	Feng Zhang
	Zehua Liu
	Nazanin Zanjanizadeh Ezazi
	Dongfei Liu
	Helder Santos, D.Sc. (Chem. Eng.)
Order of Authors Secondary Information:	
Abstract:	<p>The versatile electrospinning technique has been recognized as an efficient strategy to deliver active pharmaceutical ingredients and gained tremendous progress in drug delivery, tissue engineering, cancer therapy, and disease diagnosis. The current review presents numerous drug delivery systems fabricated through electrospinning regarding the carrier compositions, drug incorporation techniques, release kinetics and the subsequent therapeutic efficacy. Targeting for distinct applications, the composition of drug carriers vary from natural/synthetic polymers/blends, inorganic materials and even hybrids. Various drug incorporation approaches through electrospinning are thoroughly discussed with respect to the principles, benefits and limitations. To meet the various requirements in actual sophisticated in vivo environments and to overcome the limitations of single carrier system, feasible combination of multiple drug-inclusion processes via electrospinning could be employed to achieve programmed, multi-staged or stimuli-triggered release of multiple drugs. The therapeutic efficacy of the designed electrospun drug-eluting systems is further verified in multiple biomedical applications and is comprehensively overviewed here, demonstrating promising potential to address a variety of clinical challenges.</p>

1
2 DOI: 10.1002/adfm.201802852

3 **Article type: Review**
4
5
6

7 **Electrospun Fibrous Architectures for Drug Delivery, Tissue Engineering and Cancer**
8 **Therapy**
9

10
11
12 Yaping Ding*, Wei Li, Feng Zhang, Zehua Liu, Nazanin Zanjani-zadeh Ezazi, Dongfei Liu,

13 Helder A. Santos*
14

15
16 Drug Research Program, Division of Pharmaceutical Chemistry and Technology

17 Faculty of Pharmacy

18 University of Helsinki

19 FI-00014 Helsinki, Finland
20

21 *E-mail: yaping.ding@helsinki.fi; helder.santos@helsinki.fi
22
23

24
25
26
27 **Keywords: electrospinning; drug delivery; tissue engineering; cancer therapy**
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Abstract

1
2
3 The versatile electrospinning technique has been recognized as an efficient strategy to deliver
4
5 active pharmaceutical ingredients and gained tremendous progress in drug delivery, tissue
6
7 engineering, cancer therapy, and disease diagnosis. The current review presents numerous drug
8
9 delivery systems fabricated through electrospinning regarding the carrier compositions, drug
10
11 incorporation techniques, release kinetics and the subsequent therapeutic efficacy. Targeting
12
13 for distinct applications, the composition of drug carriers vary from natural/synthetic
14
15 polymers/blends, inorganic materials and even hybrids. Various drug incorporation approaches
16
17 through electrospinning are thoroughly discussed with respect to the principles, benefits and
18
19 limitations. To meet the various requirements in actual sophisticated *in vivo* environments and
20
21 to overcome the limitations of single carrier system, feasible combination of multiple drug-
22
23 inclusion processes *via* electrospinning could be employed to achieve programmed, multi-
24
25 staged or stimuli-triggered release of multiple drugs. The therapeutic efficacy of the designed
26
27 electrospun drug-eluting systems is further verified in multiple biomedical applications and is
28
29 comprehensively overviewed here, demonstrating promising potential to address a variety of
30
31 clinical challenges.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1. Introduction

1 Since the first patent relating to the process and apparatus for artificial fibers using electric
2 charges was approved in 1934,^[1] electrospun architectures have been intensively investigated
3 for many decades regarding the working principles, apparatus modifications, and diverse
4 applications extending to texture industry, energy applications, and biomedical applications.^[2]
5 Ascribing to the various benefits associated with electrospun fibrous structures, such as fine
6 fiber diameter down to nanometer, highly interconnected porous architecture, extreme high
7 surface area and porosity, high loading capacity, high encapsulation efficiency, and feasibility
8 for multifunctionalization, drug-loaded electrospun structures as novel drug delivery systems
9 (DDS) are gaining increasing attentions in multiple biomedical applications (e.g., drug delivery,
10 tissue engineering and cancer therapy).^[3]

11 In principle, micro/nanofibers can be continuously produced when polymeric jets are ejected
12 from viscoelastic solutions and further stretched and elongated by electrostatic repulsion forces
13 between surface charges.^[4] By carefully manipulating on the apparatus and parameters, fiber
14 diameter distribution, pore size, porosity and spatial arrangement can be controlled and adjusted;
15 moreover, fibrous meshes with secondary structures such as porous fiber surfaces, core-shell or
16 hollow tubular structures can be further designed and generated.^[2c, 4b] Such exceptional control
17 on morphological and dimensional variations provides numerous possibilities to carry and
18 entrap a variety of drug molecules within the electrospun fibers. In case of materials and
19 compositions, either single or multiple drugs can be incorporated into polymeric matrix or
20 organic/inorganic composite matrix. Through technical management, drugs can be either
21 evenly distributed **within** the fibers or locally concentrated in the outer or inner layer of fibers.^[5]
22 In view of release **behavior**, drugs could be released in a rapid, sustained, bi-phasic or zero-
23 order manner, to **meet** specific therapeutic needs.^[6] **Regarding** the **superiority to conventional**

1 **DDS**, electrospinning has its intrinsic advantages to overcome the challenges existing in
2
3 contemporary pharmaceutical research, **such as** difficulty for location-specific targeting
4
5 delivery, poor aqueous solubility of hydrophobic drugs (which amounted to nearly 40% of
6
7 marketed drugs), and chemical and physical degradation of complex and bioactive molecules.^[7]

8
9
10 Obviously, implantable therapeutic drugs-loaded electrospun scaffolds can be feasibly operated
11
12 for targeted delivery at specific tissues or organs; this top-down technique is able to molecularly
13
14 disperse hydrophobic drugs in the nanofibers or to stabilize the drugs in the amorphous form,
15
16 yielding a significant increase in the aqueous dissolution **rate**.^[8] In case of sustained release of
17
18 sensitive species, electrospun fibermats as stable formulations could act as a storage matrix and
19
20 protect them from the light, heat or degradation medium, **and** thus, ameliorate **the possible**
21
22 **degradation**.^[7a]

23
24
25 In general, the electrospinning technique **demonstrates** its great potential to create implantable
26
27 drug carriers, which could be further utilized for various biomedical applications requiring drug
28
29 delivery function. Its history, fundamental principle, governing of parameters have been
30
31 thoroughly reviewed and discussed in numerous literatures.^[2a, 2c, 3a, 4b] **However, the reported**

32
33 **reviews related to electrospun DDS are either out-of-date or within limited application fields.**

34
35 **A timely and comprehensive review focusing on the electrospun DDS for various biomedical**
36
37 **applications is necessary.** The current article will highlight the advances of electrospun DDS

38
39 achieved in the past few years to meet clinical needs, mainly in simple drug delivery, tissue
40
41 engineering and cancer therapy. The major purposes are: 1) to briefly discuss the fabrication of
42
43 DDS through electrospinning, in terms of **materials, drugs, techniques and drug release kinetics;**

44
45 2) to overview the tremendous progress and summarize perspectives for the future studies.

2. Fabrication of Electrospun Drug Delivery Systems and the Release Kinetics

Two key elements, matrix materials and therapeutic drugs, build up the DDS for the intended applications. Both components, and the adopted strategies to combine them, have decisive influence on the release behavior, including drug release duration and the trend of profiles. The most studied materials and drugs used in electrospun DDS are overviewed in this section, and their influences on the drug release behavior are also discussed.

2.1 Materials and Drugs

Although the versatile electrospinning technique enables the nanofiber formation from more than 200 polymers,^[2a] more specific requirements in different DDS could further narrow down the choosing pool of polymer matrix. Angelova and Hunkeler^[9] thoroughly categorized the polymeric biomaterials and proposed a flowchart as guidelines for rationalized polymer selection regarding the structure-property-application relationships. In this review, only the materials and drugs frequently studied in recent electrospun DDS will be briefly summarized.

2.1.1 Structural materials for electrospun DDS

Biocompatible polymers with diverse hydrophilicity/hydrophobicity, permeability, and mechanical properties are considered as promising candidates to load specific drugs aiming for distinct therapeutic efficacy. Target application is the primary consideration to determine the compositions of DDS.

In fast dissolving drug delivery systems (FDDDS), drug dosage forms are supposed to rapidly disintegrate in the oral cavity, therefore hydrophilic biopolymers are considered as optimal candidates to carry the drugs, such as poly (vinyl alcohol) (PVA)^[10], polyvinylpyrrolidone (PVP)^[11] and gelatin^[12]. For a local drug delivery to the oral mucosa, cross-linked gelatin was

1 electrospun to form patches containing antifungal agents due to its biocompatibility and
2 mucoadhesive property.^[13] The varying cross-linking degrees of gelatin allow the adjustable
3 and sustained release of antifungal agents in the oral cavity to maintain the therapeutic level.^[14]
4
5

6
7 To fabricate an oral formulation for drug releasing *via* the sublingual route, PVA/sodium
8 alginate blend was chosen as the patch matrix to enable sustained drug release over 10 h.^[15]
9

10 Due to the pH sensitive feature, some smart materials, such as shellac and Eudragit S100, can
11 prevent the drug release in low pH and allow rapid drug release in neutral pH condition, making
12 them highly applicable for oral colon-targeted drug delivery.^[16] Biodegradable and
13 biocompatible fibrous patches, such as poly(lactic-co-glycolic acid) (PLGA),^[17] cellulose
14 derivatives,^[18] polyurethane (PU),^[19] chitosan,^[20] PVP,^[21] PVA,^[22] polycaprolactone (PCL),^[23]
15 and polylactic acid (PLA) family,^[24] can be produced from electrospinning to administrate
16 drugs *via* transdermal drug delivery, since the high porosity and surface area of electrospun
17 fibers could greatly enhance the drug diffusion and thus drug accumulation efficiency in
18 comparison to the cast films.^[17a]
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33

34 A wide range of polymers were reported to act as the matrix in drug carriers for tissue
35 engineering, which required controlled drug release and simultaneous physical support for
36 tissue regeneration.^[25] The polymeric matrix is supposed to degrade gradually as the neotissue
37 growth and therapeutic agents will be subsequently released from the matrix *via* both diffusion
38 paths and matrix degradation.^[26] Natural polymers, such as collagen, chitosan, gelatin and
39 hyaluronic acid attracted great attentions due to their unique cellular affinity. However, their
40 applications were mainly limited by the inadequate mechanical strength and low stability in
41 physiological conditions.^[25] Synthetic biopolymers represent the majority materials applied in
42 both tissue engineering and drug delivery applications, due to the feasible tunability in
43 physiochemical and mechanical performances and scaffolds configurations for specific
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59

1 requirements.^[27] Polymers, such as PLA/PLLA,^[28] PLGA,^[29] polyhydroxyalkanoates
2
3 (PHAs),^[30] and PCL,^[31] were the representatives and extensively studied in recent years.

4
5 Nevertheless, single polymer usually cannot fulfill the requirements in the complex *in vivo*
6
7 environments, therefore polymer blending is a simply approach to adjust the physicochemical
8
9 features and degradation rates of the fabricated scaffolds. For example, the blending of stiff and
10
11 flexible polymers in the scaffolds could combine and balance the stiffness and elasticity;^[32] the
12
13 blending of natural polymers with synthetic polymers endowed the scaffolds with both cell-
14
15 affinity feature and high mechanical properties;^[31a, 33] the blending of varying ratios of water-
16
17 soluble materials with hydrophobic polymers can adjust the medium penetration rate and
18
19 subsequent drug diffusion rate and release profiles.^[34] For instance, in the study of Zhu *et al.*^[34a],
20
21 up to 50 wt.% of PEG was blended with PLLA fibers to adjust the release behavior of
22
23 papaverine. **In vitro** drug release studies showed that blended fibers with PEG ratios of 20%,
24
25 30%, 40% and 50% exhibited complete drug release on days 13, 11, 8 and 4, respectively.

26
27 Most electrospun drug carriers are fabricated from polymers due to their flexibility and feasible
28
29 processability. However, in some fields, e.g., disease diagnosis, inorganic nanofibers exhibited
30
31 better performances owing to their unique physiological performances. For instance, ZnO
32
33 nanofibers were reported to provide an excellent electrical conduction path between biomarkers
34
35 and electrodes, and enabled the creation of a biodevice with hypersensitivity.^[35] Ali *et al.*^[36]
36
37 reported the fabrication of mesoporous ZnO nanofibers through electrospinning of the precursor
38
39 solution and created a highly efficient and reproducible immunosensor by conjugating the ZnO
40
41 nanofibers with a biomarker (anti-ErbB2; epidermal growth factor receptor 2) to diagnose the
42
43 early breast cancer. **This** platform should also apply for other cancer detection through
44
45 conjugation with corresponding biomarkers, making it a superior immunosensor with higher
46
47 stability, rapid response, selectivity and simplicity.^[36] In a study of Jang *et al.*^[37], SnO₂
48
49
50
51
52
53
54
55
56
57
58
59

1 nanotubes with bimodal meso- and micro-pores were synthesized through modified
2 electrospinning and then loaded with Pt catalyst to directly monitor simulated diabetic breath.
3 Unlike polymer nanofibers, inorganic nanofibers or tubes were usually fabricated through
4 electrospinning in combination with a sacrificial templating route. Therefore, the precise
5 control on post-treatments after electrospinning, including drying and calcination, was able to
6 customize the fiber morphology and therefore modulate the resultant functions.^[38] Furthermore,
7 drug delivery systems based on polymeric/inorganic composite materials were fabricated to
8 combine the advantageous merits of both organic and inorganic materials.^[39]
9
10
11
12
13
14
15
16
17
18
19
20
21

2.1.2 Smart materials for electrospun DDS

22 Stimuli-responsive polymers play important roles in DDS due to their rapid changes in
23 conformation, solubility, morphological or mechanical performances when exposed to the
24 external stimuli, such as pH, temperature, light, ultrasound, electric or magnetic field.^[40] The
25 high surface-to-volume ratio and porosity of electrospun scaffolds allow fast diffusion of
26 stimulus and rapid contact with fibers resulting hypersensitive responses. Electrospinning of
27 these stimuli-responsive polymers thus opened-up new horizons for on-demand DDS in many
28 applications, e.g. oral drug delivery, tropical cancer drug administration or sequential drug
29 release in tissue engineering.^[40-41]
30
31
32
33
34
35
36
37
38
39
40
41
42
43

44 Eudragit polymers represent a type of pH-sensitive polymers that were developed based on the
45 functionalization of methacrylic acids. By varying the composition ratios, Eudragit polymers
46 soluble in fluids of distinct organs at different physiological pH were synthesized and widely
47 applied in oral drug formulations.^[42] For instance, Eudragit E 100 can only be dissolved in
48 gastric fluid up to pH 5,[]] Eudragit L 100 (EL100) was designed to be dissolved in intestinal
49 fluid above pH 6 and Eudragit S 100 (ES100) above pH 7.^[43] Yang *et al.*^[16b] and Jin *et al.*^[44]
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 prepared ES100 (shell)/lecithin-diclofenac sodium(core) and ES100(shell)/indomethacin (core)
2 fibrous scaffolds to protect the drug from acid gastric fluid and achieve colon-targeted release.
3 Han *et al.*^[43] comparatively studied the pH-responsive release of two model drugs from EL100
4 (core)/ES100 (shell) and ES 100 (core)/EL100 (shell) core-shell fibers and demonstrated multi-
5 pH responsive and selective pH-responsive performances of the different Eudragit polymer
6 combinations (**Figure 1a**). Additionally, new class of pH sensitive copolymers, such as poly(4-
7 vinylbenzoic acid-co-(ar-vinylbenzyl)trimethylammonium chloride) [poly(VBA-co-VBTAC)],
8 was synthesized and electrospun into nanofibers to deliver ciprofloxacin in response to acid,
9 neutral or basic conditions.^[45]

10 Poly (N-isopropylacrylamide) (PNIPAM) is widely applied in thermos-responsive systems
11 since it is able to reversibly switch its swelling state below lower critical solution temperature
12 (LCST, at 32°C) and the deswelling state above LCST.^[46] Li *et al.*^[47] embedded P(IPAAm- co-
13 AAc) nanogels within the PCL shell of drug-loaded electrospun fibers. The deswelling of
14 embedded nanogels above 40°C created cavities and diffusion paths around the gels and
15 allowed rapid drug release, whereas the re-swelling of nanogels then closed the cavities
16 resulting delayed drug release (**Figure 1b**). Similarly, electrospun PNIPAAm/ethyl cellulose
17 fibers loaded with ketoprofen were applied to achieve on-demand drug release in responsive to
18 temperature.^[48] A copolymer of poly(N-isopropylacrylamide-co-methacrylic acid) (PNIPAM-
19 co-MAA), which combined the stimuli-responsive features of both PNIPAM and methacrylic
20 acids, is responsive to both temperature and pH simultaneously.^[49] In a study of Yuan *et al.*
21 ^[50], electrospun chitosan-graft-poly(N-isopropylacrylamide) (CTS-g-PNIPAAm) fibrous
22 scaffolds showed responsive feature to both pH and temperature, since chitosan was reported
23 to be pH-sensitive owing to the ionization of the amino groups. Li *et al.*^[51] incorporated gold
24 nanorods with photothermal effect into doxorubicin (DOX)-loaded PNIPAM cross-linked

1 fibers through electrospinning, thereby fabricating hybrid scaffolds with near-infrared (NIR)
2
3 light-driven and subsequent temperature-triggered drug release. In their study, the heat-up of
4
5 gold nanoparticles upon exposure to NIR light could initiate the shrinkage of PNIPAM and then
6
7 speed up the drug release.
8
9

10 In a study of Song *et al.*,^[52] the authors proposed that the ultrasound irradiation could trigger
11
12 the on-demand drug release from a dual-drug-loaded PLGA composite fibers containing both
13
14 fluorescein (FLU) and rhodamine B-loaded mesoporous silica nanoparticles (RHB loaded
15
16 MSNs) (**Figure 1c**). The enhanced drug release both from PLGA fibers and MSNs was
17
18 attributed to the elevated temperature, which can be controlled through ultrasonic stimulation.
19
20 By selectively manipulating the ultrasonic powers and pulsed cycles, on-demand drug release
21
22 can be easily achieved.
23
24
25

26
27 Han *et al.*^[53] synthesized a self-immolative polymer (SIP) and then fabricated SIP/
28
29 polyacrylonitrile (PAN) fibers with PVP/dye in core section through co-axial electrospinning
30
31 (**Figure 1d**). Due to the extremely high surface area, nano-sized diameter and high porosity,
32
33 SIP in the fiber shell could display very fast and responsive depolymerization upon external
34
35 stimuli, resulting in on-demand drug release.
36
37
38

39
40 The magnetic-field responsive feature was normally introduced by magnetic nanoparticles, i.e.,
41
42 iron oxide nanoparticles (IONPs). Wang *et al.*^[54] created drug-loaded magnetic fibers by
43
44 loading IONPs into PCL shell and confining ketoconazole within PCL hollow core through co-
45
46 axial electrospinning. The release study showed that the introduction of an auxiliary magnetic
47
48 field could accelerate the ketoconazole release due to the intensified motion of molecules
49
50 activated by IONPs.
51
52
53
54
55
56
57
58
59

Additionally, the promising applications of other electrospun systems for tumor-triggered drug release^[55], and inflammation-sensitive release^[56] were also explored. These systems are further discussed later in this review.




Figure 1. Several representative studies of stimuli-responsive drug release systems *via* electrospinning. (a) Electrospun core-shell fibers from pH-responsive polymers: (1) ES 100(shell)/EL100 (core) and (2) ES100 (core)/EL100 (shell). Reproduced with permission;^[43] Copyright 2017, American Chemical Society. (b) Electrospun core-shell fibers using temperature-sensitive P(NIPAM-co-AAC) nanogels as valve to achieve temperature-responsive drug release. Reproduced with permission;^[47] Copyright 2015, John Wiley and Sons. (c) Ultrasound-triggered drug release from PLGA composite fibers. Reproduced with permission;^[52] Copyright 2015, Oxford University Press. (d) Electrospun self-immolative

1 polymer/PAN core-shell fibers for stimuli-responsive drug release. Reproduced with
2 permission,^[53] Copyright 2017, American Chemical Society.
3
4
5
6
7

8 2.1.3 *Multiple drugs involved in electrospun DDS*

9

10 As the key **component** in DDS, drugs are also known as active pharmaceutical ingredients
11 (APIs), which have the responsibility to achieve satisfactory therapeutic efficacy. In current
12 biomedical applications, APIs not only indicate the traditional small-molecule drugs, but also
13 refer to all the ingredients that have desired **therapeutic** functions.
14
15
16
17
18
19
20

21 To achieve antibacterial function, a large range of antibiotics were encapsulated into fibers
22 through electrospinning, such as tetracycline, cefoxitin, amoxicillin, gentamycin or
23 ciprofloxacin.^[57] The simple process of electrospinning usually allows the feasible addition of
24 large amount of antibiotics; and the drug inclusion could also affect the solution properties,
25 such as viscosity, conductivity and thereby influence the fiber structures. However, a higher
26 risk of burst release often associated with the antibiotics/polymer **systems** due to the
27 incompatibility between **hydrophilic drugs and hydrophobic polymers**.^[31a] Moreover, the
28 incorporation and release of silver, titanium dioxide, and zinc oxide nanoparticles from
29 electrospun fibers have also been investigated to prevent the inflammation and infections.^[57-58]
30
31 In addition to the antibacterial function, some other biological enhancements could also be
32 achieved, such as the improved osteoconductivity introduced by zinc oxide for an application
33 in periodontal membrane.^[58b]
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Anti-cancer drugs are another group of APIs which were intensively investigated in drug carrier
52 systems for cancer therapy. Electrospun fibers containing paclitaxel, doxorubicin, camptothecin,
53 hydroxycamptothecin, bortezomib, temozolomide, titanocene dichloride, daunorubicin,
54 cisplatin were widely explored for chemotherapy to treat glioma, breast cancer, lung cancer,
55
56
57
58
59
60
61
62
63
64
65

1 skin cancer, leukemia, and avoid tumor recurrence.^[34b, 55, 59] Additionally, IONPs were co-
2
3 incorporated with bortezomib by Sasikala *et al.*^[55b] to achieve combined hyperthermia therapy
4
5 and chemotherapy. In a study of Zhang *et al.*^[60], multi-walled carbon nanotubes were co-
6
7 blended with doxorubicin in PLLA fibers to combine photothermal therapy and chemotherapy.
8
9
10 Growth factors, peptides and genes representing the biologically active molecules could also
11
12 be encapsulated and delivered through electrospun fibers to regulate and modulate the
13
14 biological signals between cells and the extracellular matrix (ECM) for tissue regeneration.^[61]
15
16 For instance, basic fibroblast growth factor (bFGF) and endothelial growth factor (EGF) were
17
18 embedded in collagen and hyaluronic acid fiber to accelerate epithelialization and vasculature
19
20 sprouting, whereas vascular endothelial growth factor (VEGF) and platelet-derived growth
21
22 factor (PDGF) were expected to induce blood vessels maturation.^[62] Recombinant human
23
24 transforming growth factor- β 1 (rhTGF- β 1) was confined within PCL fibers to stimulate
25
26 chondrogenic differentiation of bone marrow-derived stem cells (BMSCs).^[63] Nerve Growth
27
28 Factor (NGF)-loaded PCL fibers were proved to sustainably induce the neuronal
29
30 differentiation.^[64] In a study of Li *et al.*^[65] to repair critical-sized rat calvarial defect, bone
31
32 morphogenetic protein-2 (BMP-2) was loaded to obtain osteoinductivity. For gene delivery,
33
34 nonviral vehicles such as plasmid DNA or small nucleic acids and viral vehicles such as
35
36 recombinant adeno-associated viral (AAV), have been promisingly applied in gene therapy.
37
38 Aiming for vascular tissue regeneration, Zhou *et al.*^[66] loaded microRNA-126 complexes
39
40 within the inner layer of a bilayer tubular scaffold through dual-power electrospinning since
41
42 microRNA-126 could essentially manipulate the vascular integrity and angiogenesis via
43
44 regulating the angiogenic growth factors. James *et al.*^[67] included microRNA-29a into cross-
45
46 linked gelatin fibers to increase the synthesis and deposition of ECM for bone tissue
47
48 regeneration. Attributed to the low pathogenicity and persistent transgene expression of AAV,
49
50
51
52
53
54
55
56
57
58
59

1 Gu *et al.*^[68] incorporated AAV encoding green fluorescent protein (GFP) into polyester
2 urethane urea fibers as elastic epicardial patch to restore cardiac function. The
3 biomacromolecules usually are chemically unstable and have short half-life *in vivo*.
4
5 Additionally, the harsh conditions in conventional electrospinning may harm their bioactivity
6 and cause denaturation. Thus, modified electrospinning technique, such as co-axial
7 electrospinning was considered as a superior option to avoid the denaturation.

8
9
10 Living **cells** have also been successfully encapsulated into biomedical polymer fibers through
11 co-axial electrospinning to form cell-bearing fibers or scaffolds.^[69] The cell suspensions within
12 inner needle were safely shielded and protected by the outer polymer solutions and *in vitro* and
13 *in vivo* studies certified well-maintained functions of the viable cells during and after the
14 electrospinning.^[69c]

15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 **2.2 Drug Incorporation Techniques**

33
34 **As one of the major factors** for determining release kinetics, the location of drugs within fiber
35 matrix can be simply arranged through different loading techniques. The drugs can be included
36 onto the surface, within surface vicinity, throughout the whole fiber, exclusively within shell
37 layer or core layer *via* surface immobilization, blend electrospinning, co-axial electrospinning
38 or emulsion electrospinning. A secondary barrier could also be added to the system to further
39 prolong the drug release and provide the possibility for simultaneous release of multiple drugs.
40
41 The current section will focus on a comprehensive elaboration on these different drug
42 encapsulation approaches and resultant release profiles.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

2.2.1 Surface immobilization

Surface immobilization, also referring to surface coating or surface functionalization, is regarded as one of the easy approach to absorb the drug molecules onto the fiber surfaces through chemical (covalent bonding) or physical interactions (electrostatic interaction, van der Waals interaction or hydrogen bonding, etc.).^[70] As a result of the high surface-to-volume ratio of electrospun fibers, numerous adhesion sites exist for drug molecules to attach and modify the resultant performances, such as wettability, cellular adhesion and genes expression.^[71] Multiple methods were developed to achieve the functionalization via various bonding. Table 1 lists several recent electrospun drug-loaded scaffolds via surface immobilization and the associated highlights and applications are also described.

The common method for feasible coating is to immerse fibers in target solutions for passive adsorption of biomolecules. Yao *et al.*^[33a] dip-coated the PCL/chitosan scaffolds with heparin via ionic bonding between heparin and chitosan for vascular grafts application, resulting in sustained release of heparin over 37 days. Moreover, increasing the chitosan ratio could further efficiently prolong the drug release. Qiu *et al.*^[72] functionalized PCU fibers with plasma treatment and subsequent conjugation of heparin via end-point immobilization. Polydopamine (pDA) chemistry is one of the popular approaches to immobilize proteins, peptides and antibodies onto hydrophobic fiber mats to enhance the cell affinity, cell-matrix interactions and introduce specific bio-signals (Figure 2a).^[28b, 29c, 55b, 73] Oxidative self-polymerization of dopamine into pDA on fiber surface could provide abundant hydroxyl and amine groups to covalently bond with biomolecules under weak alkaline conditions. In the works of Lee *et al.* and Cho *et al.*^[28b, 29c], bone-forming peptide 1 (BFP1) and bone morphogenetic protein-2 (BMP-2) were subsequently immobilized onto PLGA and PLLA fibrous fibers, respectively, after initial self-polymerization of pDA coating. Stable retention of BMP-2 on the fiber surface can

1 be lasted up to 28 days with minimum burst release.^[28b] PDA coating itself was also reported
2
3 to be biocompatible and to enhance cell proliferation. Taskin *et al.*^[31c] collected the electrospun
4
5 PCL fibers in dopamine solution bath to form 3D coiled PCL fiber scaffolds with in-situ
6
7 polymerized pDA coatings. In addition to pDA, a di-amino-poly (ethylene glycol) linker (di-
8
9 amino-PEG), was also employed to act as an intermediate cross-linker to covalently bond mucin
10
11 onto the fibrous scaffolds.^[74] This conjugated mucin was more stable than simply absorbed
12
13 mucin under static and flow conditions.
14
15

16
17
18 **In addition to** biomolecules, organically modified glass (ormoglass) layer containing bioactive
19
20 ions was also covalently immobilized onto fiber surface through four functionalization steps:
21
22 NaOH hydrolysis, ethyl(dimethyl-aminopropyl)carbodiimide/N-hydroxysuccinimide
23
24 (EDC/NHS)treatment, immersion in 3-aminopropyltriethoxysilane (APTES) solution and
25
26 **subsequent** ormoglass coating (**Figure 2b**).^[71c] The hybrid organic/inorganic glass coating
27
28 **remarkably** enhanced the mechanical performances, wettability and roughness. Moreover,
29
30 calcium ions were sustained released for 14 days despite the burst release in the first day.
31
32
33

34
35
36 Jia *et al.*^[75] employed an inkjet printing to precisely deposit the growth factors onto fiber
37
38 surfaces (**Figure 2c**). Through optimization of printing parameters, the biomolecules and
39
40 subsequent cellular distribution were spatially organized in designed patterns. Although no
41
42 strong interactions occurred, the deposited growth factors were still remained on the fibrous
43
44 scaffold for more than 1 week, enabling the successful regulation function of TGF- β 1 on the
45
46 fibroblast differentiation. In addition, the precisely controlled deposition of biomolecules
47
48 enforces the formation of biomolecular fibrous network, which could essentially mimic the
49
50 biofunctions *in vivo* conditions.
51
52
53
54
55
56
57
58
59

Since the immobilizations usually only occurred on the surface or near surface vicinity, the incorporation of drugs or biomolecules would not alter the overall physical performances and the degradation properties of the original electrospun fibers. Additionally, post-immobilization of biomacromolecules could feasibly avoid the denaturation caused by the harsh condition of organic solutions.




Figure 2. (a) Peptides immobilization onto PLGA fibers surface through pDA chemistry. Reproduced with permission;^[29c] Copyright 2013, Elsevier B.V. (b) Bioactive glass phase was coated onto the electrospun fibers through a four-step process. Reproduced with permission;^[71c] Copyright 2015, Royal Society of Chemistry. (c) Patterned biomolecule deposition onto electrospun fibermats *via* inkjet printing. Reproduced with permission;^[75] Copyright 2017, John Wiley and Sons.

Table 1. Representative electrospun DDS *via* surface immobilization and the associated highlights and applications.

Materials	Drugs	Highlights	Applications	Ref.
PCL/ Chitosan	Heparin	Drug immobilization <i>via</i> strong ionic bonding between heparin and chitosan; Burst release in 1 d followed by sustained release until 37 d.	Vascular grafts	[33a]
PCL/ Collagen	SDF1 α	Growth factors were embedded in radically aligned fibers through collagen-binding domain; Gradual release for 7 d without burst release.	Guiding nerve regeneration	[33b]
PCL /Gelatin	APA-coated AuNPs	20.4% of AuNPs were rapidly released in 1 d and then sustained released for 14 d, exhibiting striking ability to remedy multidrug-resistant bacteria wound infections.	Wound healing	[33c]
PLGA	Polydopamine Bortezomib	Bortezomib conjugation onto the fiber surface through dopamine coating; 70% vs 20% of drug was released in the first 12 h at pH 5.5 vs 7.4.	Cancer therapy	[55b]
PLA	Si–Ca–P ₂ ormoglass <i>via</i> covalent bonding	Sustained release of Ca ²⁺ ions for over 16 d; The lower the Si ⁴⁺ content, the higher the Ca ²⁺ release.	Regenerative medicine	[71c]
PCU	Heparin	PCU fibers were treated by plasma and then conjugated with heparin <i>via</i> end-point immobilization; Conjugated heparin dramatically improved the patency of vascular grafts, the early stages of endothelialization and graft integration <i>in vivo</i> .	Vascular graft	[72]
PLGA	Polydopamine, BFP1	Significant increase of newly formed bone volume after implantation of pDA-BFP1-coated scaffolds after 8 weeks.	Guided bone regeneration	[29c]
PLLA	Polydopamine, BMP-2	90% of BMP-2 remained on the fiber surface for 28 d.	Bone regeneration	[28b]
PLLA	Polydopamine, Osteogenic peptide (OP)	After 8 h of polydopamine coating, 80% of immobilized OP can be retained on the fiber surface for 28 d.	Guide bone regeneration	[73]
PCL	Polydopamine	3D-coiled fibrous scaffolds with polydopamine coating were collected in dopamine solution.	Tissue engineering	[31c]

1	PLLA	BSM conjugation	In comparison to absorbed BSM, conjugated	Vascular graft	[74]
2		<i>via</i> EDC and NHS	BSM on the fiber surface significantly improved		
3	PLCG/ PCL	coating and di- amino-PEG linker	the patency of vascular grafts, prevented thrombosis and graft occlusion.		
7	PCL/ Collagen	BSA	A biomolecule network with designed biomimetic patterns, formed on the fiber substrates by inkjet printing.	Cancer therapy	[75]
11	PLLA	Fibronectin	Fibronectin coating on fibers effectively improved astrocytic adhesion and survival.	Nerve Regeneration	[28a]
14	PCL	RGD YIGSR	Self-assembled RGD/YIGSR coating on fiber surface highly improved the cell adhesion and survival of Schwann cells, promoted axonal regeneration and enhanced vascularization.	Nerve Regeneration	[76]
20	PCL	Azithromycin	Drugs immobilization through solvent evaporation technique;	Bone Regeneration	[77]
23			All drugs were rapidly released in the first 24 h and sustained released until 14 d.		
26	Silk fibroin	Antimicrobial peptide motif Cys- KR12	Immobilization of Cys-KR12 on to electrospun silk fibers through EDC/NHS and thiol- maleimide click chemistry;	Wound healing	[78]
30			Antibacterial effect maintained for 3 wk.		

PCL, polycaprolactone; SDF1 α , stromal-cell-derived factor-1 α ; APA-coated AuNPs, (6-aminopenicillanic acid, APA)-coated gold nanoparticles; PCU, polycarbonate-urethane; PLGA, poly(lactic-co-glycolic acid); BFP1, bone-forming peptide 1; PLLA, poly(L-lactide); BMP-2, bone morphogenetic protein-2; OP, osteogenic peptide derived from BMP-2; PLCG, poly(L-lactide-co-caprolactone-co-glycolide); BSM, bovine submaxillary mucin; EDC, 1-ethyl-3-(3 dimethylaminopropyl) carbodiimide hydrochloride; NHS, N-hydroxysulfosuccinimide; PEG, poly(ethylene glycol); BSA, bovine serum albumin; RGD, arginine-glycine-aspartic; YIGSR, tyrosine-isoleucine-glycine-serine-arginine.

2.2.2 Blend electrospinning

Blend electrospinning is a one-step method to embed or encapsulate drug molecules into fiber matrix by electrospinning of miscible and stable mixture solution containing both drugs and

1 polymers. Blend electrospinning was the earliest attempt to form drug formulations through
2 electrospinning, reported by Kenawy *et al.*^[79] in 2002. They claimed that the drug release in
3 electrospun fibers was much faster than the cast films due to the high surface-volume ratio of
4 electrospun membranes and the drug release kinetics can be modulated through adjusting the
5 polymer compositions. Soon after, Zeng *et al.*^[80] investigated the decisive factors determining
6 the release kinetics of blending fibers. Their study firstly revealed that the drug solubility and
7 drug-polymer compatibility practically influenced the drug distribution throughout the fibers
8 and thus the release profiles. In blending systems, a constant and stable drug release can only
9 be achieved in lipophilic drug/lipophilic polymer or hydrophilic drug/hydrophilic polymers
10 systems. Thereafter, numerous drug/polymer systems were fabricated by blending and their
11 drug delivery functions were widely explored.^[31a, 34a, 81] **Table 2 summarizes the recent drug-**
12 **laden fibers through blend electrospinning.** Fast drug release for such as 2 h or sustained release
13 for such as 91 days can be accomplished *via* blend electrospinning when the appropriate
14 drug/polymer were chosen.^[81-82] By doping an enzyme-sensitive prodrug (poly(ibuprofen)) into
15 polymer poly(hydroxyethyl methacrylate) (PHEMA) fibers *via* blend electrospinning (**Figure**
16 **3a**), Pan *et al.*^[83] successfully managed a polymer degradation-synchronized drug release for
17 14 weeks (accelerated drug release when polymer underwent self-catalyzed degradation). Apart
18 from the drug molecules, (6-aminopenicillanic acid, APA)-coated gold nanoparticles (AuNPs)
19 were also doped into PCL/gelatin fibers to resist multidrug-resistant bacteria and promote
20 wound healing (**Figure 3b**).^[33c]

21 Obviously, blending is the simplest strategy to achieve drug delivery through electrospinning.
22 The limitation of blend electrospinning is that biomolecules may denature in case of harsh
23 organic solvents and incompatible drug/polymer systems may generate uncontrolled release
24 behaviors.^[84]




Figure 3. (a) Prodrugs were encapsulated in polymer fibers through blend electrospinning. Reproduced with permission;^[83] Copyright 2015, Elsevier B.V. (b) PCL/gelatin fibers containing modified gold nanoparticles were fabricated through blend electrospinning. Reproduced with permission;^[33c] Copyright 2017, American Chemical Society.

Table 2. Representative electrospun DDS *via* blend electrospinning and the associated highlights and applications.

Materials	Drugs	Highlights	Applications	Ref.
PCL/ gelatin	MNA	An initial burst release in 3 d (60%) and sustained release for 21 d.	Guided tissue regeneration	[31a]
PLLA/ PEG blend	Papaverine	Papaverine can be rapidly released in the first 2~7 d and then sustainably released until 14 d by varying the polymer blend ratios.	Preventing vasospasm	[34a]
PEO/PCL blend	Niclosamide	Gradual release of 40% of niclosamide over 21 d, following the Korsmeyer–Peppas model.	Cancer therapy	[34c]
PCL/ PGC-C ₁₈ blend	Cisplatin	Linear drug release over 90 d due to the blend superhydrophobic fiber meshes.	Anti-lung cancer recurrence	[59a]
BPU	Dipyridamole	Sustained Drug release over 91d due to the good compatibility; The higher the drug ratio, the slower the drug release.	Vascular grafts	[81]

PCL	PIBU	Incorporation of enzyme sensitive prodrug PIBU through blend electrospinning; Combination of initial enzyme-triggered release - moderate release of anti-inflammatory drugs and degradation-synchronized drug release in the later-stage over 14 wk.	To prevent biodegradation-induced inflammation	[83]
PCL, PNIPAAm	Nattokinase	Core-shell structure with thermal-responsive shell was self-assembled during the electrospinning; The thermal-responsive shell allowed faster drug release above the phase transition temperature (32°C), therefore resisted the platelet adhesion and facilitated red blood cells capture.	To capture red blood cells for diagnosis	[85]
PLGA	Poly-L-lysine covalently conjugated with YIGSR and RGD	Two adhesive peptides were uniformly distributed on the surface and inside of fibers, significantly enhancing the adhesion of cardiomyocytes.	Cardiac tissue engineering	[29b]
PLLA	Oxaliplatin Dichloroacetate	Fabrication of multilayer scaffolds with dual-drug-loaded layers through co-electrospinning; Time-programmed dual-release behaviors over 30 d.	Anti-cancer recurrence	[86]
PELCL (inner) PCL/ gelatin (outer)	MiR-126	Fabrication of multilayer tubular electrospun scaffolds through dual-power electrospinning; Sustained release of 60% of miR-126 over 56 d.	Blood vessel regeneration	[66]
Gelatin	MiR-29a	Burst release of miR-29a in 2 h and then sustained release over 72 h.	Tissue engineering	[67]
PLCL/ PEOz blend	VEGF and bFGF	Dual-growth factors release; Burst release of both growth factors in 7 h and then sustained release over 240 h.	Cardiac tissue regeneration	[87]
PCL	Methylcobalamin	Sustained release of less than 15% of drug over 8 weeks.	Nerve regeneration	[88]
PVA	Antifungal Cm-p1	Burst release in 2 h and following sustained release up to 3 d.	Anti-fungal infection	[89]
Gelatin	Polyhydroxy antibiotics (pDA)	Fiber fabrication through in-situ cross-linking of gelatin, pDA and antibiotics <i>via</i> strong interfacial interactions, resulting in extended antibacterial activity up to 20 d.	Antimicrobial-wound dressings	[90]

1	PLA	Paclitaxel	Drug release in concentration-dependent manner;	Nerve	[91]
2			Scaffolds with drug ratios from 0.02% to 3.26%	regeneration in	
3			all can gradually release the drugs over 84 d.	spinal cord	
4					
5	PLLA	TSA	Sustained release of less than 35% of TSA from	Tendon tissue	[92]
6			aligned fibers over 90 h, following the Higuchi	engineering	
7	PEO		equation;		
8			Aligned fiber orientation delayed the drug release		
9			rate in comparison to random fiber meshes.		
10					
11					
12					
13	PEO,	polyethylene oxide;	PGC-C18,	poly(caprolactone-co-glycerol-monostearate);	BPU,
14					
15		biodegradable elastic polyurethane urea;	PIBU,	poly (ibuprofen);	PNIPAAm,
16					poly(N-
17					isopropylacrylamide);
18					PELCL,
19					poly(ethylene glycol)-b-poly(L-lactide-co-e-caprolactone);
20					mir-126,
21					microRNA-126 complexes;
22					miR-29a,
23					microRNA-29a complexes;
24					PLCL,
25					poly(L-lactide-co-
26					caprolactone);
27					PEOz,
28					poly (2-ethyl-2-oxazoline);
29					VEGF,
30					vascular endothelial growth factor;
31					bFGF,
32					basic fibroblast growth factor;
33					Cm-p1,
34					cencritchis muricatus peptide 1;
35					TSA,
36					Trichostatin A.

2.2.3 Co-axial/ tri-axial electrospinning

High initial burst drug release often occurred in the fibers fabricated through direct blend electrospinning. The locally elevated drug concentration could cause cellular toxicity, and the short release period could not ensure the healing efficacy in many cases. Therefore, there is a demand for innovative modifications and alternatives to alleviate the burst release. Co-axial electrospinning, which was firstly reported by Sun *et al.*^[93] in 2003, utilized a spinneret consisting of two concentrically aligned capillaries to push immiscible inner and outer solutions simultaneously for generating core-shell fibers. The second separate core nozzle enables the encapsulation of sensitive, water-soluble and bioactive molecules possible, and the deleterious effects from organic solvents can be avoided. Even unspinnable drug solution can be utilized in co-axial electrospinning, thus ultra-high drug loading into the central section could be realized independent of the solubility and viscosity of the drug solute.^[94]

Table 3 summarizes the recent drug-laden fibers through co/tri-axial electrospinning. Various chemicals and bioactive agents for drug delivery and tissue engineering, such as growth factors, nucleic acids and living organisms, can be incorporated into the core section without losing their functions.^[95] When shielded from the shell polymer, central-located bioactive agents can only be released through nano-path diffusion and/or shell polymer degradation. Therefore, by varying the composition of shell polymers, sustained release or sequential release of multiple drugs can be feasibly achieved.^[96] For instance, rapid drug release profile was shown in case of hydrophilic polymeric shell and slow and sustained release profile can be obtained in case of hydrophobic polymeric shell.^[44, 68, 94] Additionally, the release time-scale can be adjusted simply through altering the fiber surface texture and shell thickness (relevant to feeding rate of outer and inner solution).^[97] Moreover, the interactions between inner and outer solutions were also reported to affect the release kinetics. Angkawinitwong *et al.*^[98] discovered that the pH of core solutions could greatly influence the core-sheath structure and thus the release kinetics when they incorporated bevacizumab into PCL fibers through co-axial electrospinning. As shown in **Figure 4a**, the positively charged bevacizumab could uncontrollably migrate from the core solution to the PCL sheath solution, resulting in the inhomogeneous distribution of drug in both shell and core section, and thus a first order release up to 18 days. However, the neutral charged bevacizumab could be finely confined in the core section, forming a well-defined core-shell structure, and thus a zero-order release of drug up to 60 days.

To meet the demand of body temperature-stimuli responsive drug release, Li *et al.*^[47] created a thermally switched drug release device through co-axial electrospinning. Thermally responsive nanogels, which were embedded into the PCL shell to act as valves, generated cavities as paths for the diffusion of encapsulated drugs during the shrinking and swelling at above or under LCST (**Figure 4b**). As an extension of co-axial electrospinning, tri-axial electrospinning

provides more possibilities to modify the materials, fiber structures and release kinetics. Yu *et al.*^[99] used tri-axial electrospinning to synthesize a tri-layer composite fiber with drug gradient distribution (**Figure 4c1**). The drug content of the fibers was gradually increased from outer layer to middle and inner layer, which comprised a **system** to stably release the drug in a zero-order manner (**Figure 4c2 and c3**).

In summary, co-axial/tri-axial electrospinning could provide feasibility for **sustained and multistage drug release**. More importantly, co-axial/tri-axial electrospinning widen the drug solution range to unspinnable fluids.^[99-100] The limitations of co-axial/tri-axial electrospinning are mainly the complexity of the set-up configuration, and various working parameters need to be well controlled and the interfacial tension of inner and outer solutions need to be well adjusted.


Table 3. Representative electrospun drug-loaded scaffolds *via* co-/tri-axial electrospinning and the associated highlights and applications.

Materials	Drugs	Highlights	Applications	Ref.
Shell	Core			
ES100	Diclofenac sodium phospholipids	Drug release in two stages <i>via</i> pH-responsive manner; The ES100 shell dissolved in acid condition firstly (pH 1.0, 2.1% of drug release in 2 h); Released drug phospholipids further gradually released the drug at pH 7.0, which reached 79% over 22 h.	Oral colon-targeted drug delivery	^[16b]
ES100	Gd(DTPA)-loaded PEO and indomethacin	Therapeutic and imaging agents were delivered simultaneously to the colon. Indomethacin had less than 10% of release at pH 1 and sustained release over 29 h at pH 7.4.	Oral drug delivery	^[44]

1 2 3 4 5	PCL/ nanogels	Methyl orange loaded PEO / DOX-loaded PEO	The swelling and shrinking of thermal responsive nanogels (LCST 32 °C) located in the shell could create cavities as drug diffusion paths to control the drug release in response to temperature.	Drug delivery system [47]
6 7 8 9 10	Chitosan/ PVA blend	Curcumin	Delayed drug release; Rapid release of 40% of curcumin in 8 h and sustained release of 73% of drug over 10 d.	Wound healing [94]
11 12 13	PEUU and PEEUU	AAV-loaded PEO	Sustained transgene expression over 2 months.	Cardiac tissue engineering [68]
14 15 16 17 18	SF/CS/ nHAP	BMP-2	Sustained release of BMP-2 over 22 d; Fibers with thin shell thickness could release drugs in faster rate.	Bone tissue engineering [97]
19 20 21 22 23 24 25	PCL	Bevacizumab	pH of core protein solution had influences on the resultant core-shell structure; With varying the pH, drugs can be released following a first-order kinetic ($t_{1/2}$ of 11.4 d) or a zero-order kinetic ($t_{1/2}$ of 52.9 d).	Age related macular degeneration [98]
26 27 28 29 30	Ethyl cellulose	Ethyl cellulose /ketoprofen	Fibers with gradient distribution of drugs were prepared through tri-axial electrospinning; Linear drug release over 20 h.	Drug Delivery Systems [99]
31 32 33 34 35 36 37	P(LLA- CL)/silk fibroin/ PANi	NGF/BSA	Sustained release of NGF from conductive core- shell fibers over 5 d, increased the percentage of neurite-bearing cells and median neurite length; NGF release was increased by electrical stimulation.	Neural tissue engineering [101]
38 39 40 41 42	PCL CA	PVP/Nisin	Fabrication of fibers with three layers through tri- axial electrospinning; Biocidal activities were retained over 5 d.	Wound healing [102]
43 44 45 46 47 48	PLGA /EGCG	Hyaluronic acid	Uniform distributed EGCG in PLGA shell was released in a stepwise manner for 28 d; Central-located hyaluronic acid was sustained released for 28 d.	Diabetic wound healing [103]
49 50 51 52 53 54	PCL/Ag	Hyaluronic acid/ PEO	Complete release of Ag within 4 d; Initial rapid release of hyaluronic acid in 10 d and following sustained release over 21 d.	Anti-peritendinous adhesion [104]

ES100, Eudragit S100; Gd(DTPA), Gd(III) diethylenetriaminepentaacetate hydrate; LCST, lower critical solution temperature; DOX, doxorubicin; PVA, polyvinyl alcohol; PEUU, polyester urethane

1 urea; PEEUU, polyester ether urethane urea; AAV, recombinant adeno-associated viral; SF, silk fibroin;
 2
 3 CS, chitosan; nHAP, nanohydroxyapatite; P(LLA-CL), poly(L-lactic acid-co-3-caprolactone); PANi,
 4
 5 polyaniline; CA, cellulose acetate; PVP, polyvinylpyrrolidone; EGCG, epigallocatechin-3-O-gallate.
 6



41 **Figure 4.** (a) A diagram illustrating the influence of pH of drug solution on the fiber structure,
 42 drug distribution, and release kinetics when produced through co-axial electrospinning.
 43
 44 Reproduced with permission;^[98] Copyright 2017, Elsevier B.V. (b) Thermal responsive fibers
 45 using shell-located nanogels as valve were fabricated through co-axial electrospinning.
 46
 47 Reproduced with permission;^[47] Copyright 2015, John Wiley and Sons. (c) A study of tri-layer
 48 drug-loaded fibers through tri-axial electrospinning process. (1) Schematic illustration of the
 49 tri-axial electrospinning. (2) SEM images of the fabricated tri-layer fibers. (3) The linear release
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65


1 profile was achieved by the tri-layer drug-loaded fibers. Reproduced with permission;^[99]
2
3 Copyright, 2015, American Chemical Society.
4
5
6
7

8 2.2.4 Emulsion electrospinning 9

10 Sanders *et al.*^[105] reported the first emulsion-electrospun fibrous structure in 2003. A two-phase
11 W/O emulsion of BSA-water/poly (ethylene-covinyl acetate)-dichloromethane was used to
12 enforce fiber formation through a single nozzle, generating a core-shell structure when the water
13 droplets were stretched and solidified. Usually three phases comprise the spinnable emulsion:
14 aqueous phase, oil phase and sometime surfactants, which enhance the stability of the W/O
15 emulsion and influence the release behaviors (Figure 5a).^[30a, 106] The emulsion stability, which
16 is the essential factor determining the successful entrapment of biomolecules, can be maintained
17 by choosing the appropriate surfactant, emulsification parameters and electrospinning
18 parameters.^[107] These factors synergically affect the successful spinning and the distribution of
19 the bioactive molecules (either a core-shell structure or drug randomly embedded in matrix).
20 Moreover, Yazgan *et al.*^[108] found that relative humidity (RH%) and surfactant concentration
21 had remarkable influences on the fiber structure, surface morphology, surface chemical
22 composition and consequently the drug release kinetics in emulsion electrospinning. They
23 proposed that optimized surfactant concentration with high RH% can render porous fiber
24 surface, leading to rapid drug release. With increasing the concentration of surfactant Span 80,
25 dense fiber surface can be formed, resulting in delayed drug release. In addition to the usually
26 reported W/O emulsion, Basar *et al.*^[109] synthesized PCL/ketoprofen(core)/gelatin(shell) fibers
27 via electrospinning from an O/W emulsified suspension. The cross-linked gelatin was
28 considered as a coating outside of the ketoprofen-loaded PCL fibers, and thus extended the drug
29 release period from 20 h to 100 h. Moreover, the physical performance of PCL and the cellular
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 affinity of natural gelation were combined for wound healing applications. **Table 4** further
 2 summarizes the recent drug-loaded electrospun structures from emulsion electrospinning and
 3 describes the highlights.
 4
 5
 6

7
 8 Compared to co-axial/tri-axial electrospinning, emulsion electrospinning is a simpler one-step
 9 process to form core-shell fibers without complicated spinneret configuration. Water-soluble
 10 and fragile biomolecules can also be well confined in the core section of fibers *via* emulsion
 11 electrospinning (**Figure 5b**). Their release kinetics were mainly determined by the diffusion
 12 and degradation of polymer shell as well. However, the addition of water phase into polymer
 13 solution could greatly affect the viscosity, surface tension and conductivity of original polymer
 14 solutions, therefore influence the fiber topography and the mechanical performances of the final
 15 drug-loaded fibrous scaffolds.^[110]
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26



41 **Figure 5.** (a) An example of emulsion electrospinning process from W/O emulsions.
 42 Reproduced with permission;^[111] Copyright 2014, Elsevier B.V. (b) Schematic illustration on
 43 the mechanism of the core-shell structure formation during the emulsion electrospinning
 44 process. Reproduced with permission;^[112] Copyright 2006, John Wiley and Sons.
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65

Table 4. Representative electrospun DDS *via* emulsion electrospinning (core-shell structure) and the associated highlights and applications.

Materials	Drugs	Highlights	Applications	Ref.
PCL PHBV (Oil phase)	Metformin hydrochloride or Metoprolol tartrate (Water phase)	The influences of polymer compositions, surfactants and drug characteristics on the release profiles were investigated; Slower and sustained drug release can be achieved over 21 d in comparison to blend electrospinning.	Drug delivery System	[30a]
PS PVP (Oil phase)	Fluorescein sodium salt (Water phase)	The higher the humidity, the more porous of the fiber surface leading faster drug release. With increasing the surfactant concentration, dense fiber surfaces could form, resulting in delayed drug release.	Drug delivery System	[108]
Gelatin (Water phase)	Ketoprofen in PCL (Oil phase)	PCL/drug fibers were coated with a cross-linked gelatin through emulsion electrospinning of an unusual O/W system, resulting in sustained drug release for 100 h.	Wound dressing	[109]
PLLA (Oil phase)	VEGF (Water phase)	10% of release in 1 d, and then sustained release over 4 wk.	Cardiovascular diseases	[113]
PLLA	Mitomycin-C loaded hyaluronan	Burst release of 26% of drug in 2 d and then sustained release over 40 d; The release pattern can be adjusted through altering the drug concentration.	Tendon healing	[114]
PCL gelatin	PRP-derived multiple growth factors	Simultaneous delivery of multiple growth factors, such as FDGF, FGF, TGF- β 1; Burst release in 5 d and following sustained release for 30 d.	Cartilage regeneration	[115]

PHBV, poly(3-hydroxybutyric acid-co-3-hydroxyvaleric acid); PS, polystyrene; PRP-derived, Platelet-rich plasma-derived; FDGF, platelet-derived growth factor; FGF, fibroblast growth factor; TGF- β 1, transforming growth factor-beta.

2.2.5 Secondary carrier electrospinning

In addition to the fibrous structures as backbone, secondary carriers like micelles, liposomes, nanogels, nanoparticles and nanotubes, can be physically entrapped into the fibers to form nano-in-nano or nano-in-micro structures for multi-purpose drug delivery. In theory, multiple drug-loaded particles could be delivered simultaneously resulting in multi-drug release.

Table 5 lists the recent studies on electrospun DDS containing secondary carriers, and their highlights and applications are summarized. Technically, drug-loaded secondary carriers were dispersed into the polymer solution (with or without drugs) prior to blend electrospinning, and a co-delivery of multiple drugs was achievable according to specific requirements. The hierarchical drug delivery systems were appealing owing to the multi-barrier function, which can not only protect bioactive molecules from harsh environment and degradative conditions, but also allow sequential release of drugs under appropriate triggers.^[116] In addition, prolonged drug release was feasibly achieved due to the added physical barriers or strong interactions between drugs and carriers. For instance, Chandrawati *et al.*^[117] successfully embedded β -glucuronidase-loaded liposomes within PVA fibers by blend electrospinning for enzyme prodrug therapy (Figure 6a). They reported that enzyme-loaded liposomes remained intact within PVA fibers and the release of enzyme can be mediated *via* phase transition temperature of the liposomes for at least seven weeks. This release period is much longer than the normal active period of β -glucuronidase in biomaterials (maximum 7 days). In a study of Luo *et al.*,^[34b] camptothecin was initially loaded into promicelles (PM_{CPT}) and subsequently embedded in PEG-poly(lactide) (PELA)/PEO blend fibers through blend electrospinning. Once placed in the

tumor site, PM_{CPT} were sustained released and self-assembled into folate-targeted and glutathione (GSH)-sensitive micelles, which were taken-up by the tumor cells continuously (Figure 6b). By adjusting the composition ratio of polymer blends, the constant release of PMs can be prolonged over 30 days, which significantly enhance the anti-tumor efficacy. Xue *et al.*^[118] incorporated metronidazole (MNA)-loaded halloysite clay nanotubes (HNT) into PCL/gelatin fibers through blend electrospinning. A combination of free drugs and drug-doped HNT in the fiber resulted in a burst release in 4 days and sustained release up to 20 days, providing sufficient antibacterial effect in the GTR/GBR implant membranes.

Table 5. Representative electrospun DDS *via* secondary-carrier electrospinning and the associated highlights and applications.

Materials	Drug-loaded carrier	Highlights	Applications	Ref.
EL55	Peptide-loaded PEC nano-carriers	pH-responsive nano-in-nano system for multi-stage drug release; Nanocarriers release at pH 6 and peptides release from nanocarriers at pH 7.4.	Oral drug delivery system	^[116]
PVA	β -glu-loaded liposomes	β -glu release was mediated <i>via</i> phase transition temperature of the liposomes; The active enzyme release was extended from 7 d to 7 wk.	Enzyme prodrug therapy for cardiovascular grafts	^[117]
PELA PEO	Camptothecin-loaded promicelle (PM _{CPT})	Sustained release of PM _{CPT} over 30 d; Self-assembled drug-loaded micelles on the tumor site were up-taken into tumor cells <i>via</i> FA-mediation with following drug release inside of tumor cell.	Tumor chemotherapy	^[34b]
PCL gelatin	Metronidazole-loaded halloysite nanotubes	Burst release and following sustained release of metronidazole up to 21 d.	Guided tissue regeneration	^[118]




Figure 6. (a) Enzyme-loaded liposomes were encapsulated into PVA fibers through secondary carrier electrospinning and the drug release can be mediated through the thermal phase transition of liposomes. Reproduced with permission;^[117] Copyright 2017, John Wiley and Sons. (b) Anticancer drug-loaded promicelles were embedded into blend polymer fibers through secondary carrier electrospinning. Reproduced with permission;^[34b] Copyright 2017, Elsevier B.V.

2.2.6 Combination of multiple techniques

As an extension to secondary electrospinning, the combination of two or three drug-loading approaches have been utilized frequently, because the single DDS cannot fully fulfill the

1 function in the complex *in vivo* environment and cannot meet the increasing demand to deliver
2
3 and precisely release the multi-drugs in a multi-stage or sequential manner. **Table 6** gives
4
5 **several examples that combine two or more electrospinning approaches to achieve multi-drug**
6
7 **delivery.**
8
9

10
11
12 Cheng *et al.*^[29d] functionalized the ginsenoside-Rg3-loaded fibrous scaffolds with RGD and
13
14 bFGF through pDA coating chemistry. Results indicated that surface functionalization feasibly
15
16 promoted the cellular activity without impairing the original drug loading and release behavior.
17
18

19 Man *et al.*^[63] combined co-axial electrospinning with surface functionalization to deliver two
20
21 biomolecules aiming for chondrogenic differentiation. The chondrogenic growth factor rhTGF-
22
23 b1, which was initially entrapped in the core of PCL fibers, were gradually released up to 21
24
25 days. In addition, the BMSC-specific affinity peptide E7, which was subsequently conjugated
26
27 onto the PCL fibers surface *via* covalent bonding, synchronously promoted the BMSCs
28
29 adhesion and proliferation. The drug carriers were also immobilized on the fibers surface by
30
31 Monteiro *et al.*^[119] through covalent bonding. Thiol group was firstly inserted to bond with the
32
33 amine group of chitosan fibers, and the gentamicin-loaded liposomes were then immobilized
34
35 onto the modified chitosan fibers *via* maleimide reaction to achieve steady released gentamicin
36
37 for antibacterial applications. The immobilization of drug-encapsulated liposomes onto the
38
39 fiber surface could inhibit the drug denaturation, and avoid the toxicity brought by high dose of
40
41 drug.
42
43
44
45
46
47
48
49

50
51 Li *et al.*^[65] fabricated PCL-co-PEG scaffolds with dual-drug release capability in two stages.
52
53 Dexamethasone (DEX) and BMP-2 encapsulated bovine serum albumin (BSA) nanoparticles
54
55 were embedded into the polymer scaffolds through blend electrospinning. The burst release of
56
57
58
59

1 DEX was finished in the first 8 days and the BMP-2, which was protected by two barriers, were
2 released in a sustained manner up to 35 days. This time-programmed dual-drug release
3 manifested the highest bone repair efficiency. Song *et al.*^[120] fabricated a nano-in-nano structure
4 by encapsulating vancomycin-loaded gelatin nanospheres into the silk fibroin membranes
5 through single-nozzle or co-axial electrospinning. The drug-loaded nanoparticles were further
6 entrapped within the core section of electrospun fibers, enabling an extended drug release up to
7 14 days. Similarly, Yang *et al.*^[121] successfully confined DOX-loaded FA-PCL-PEG copolymer
8 micelles in cross-linked gelatin fibers through co-axial electrospinning. A step-wise release of
9 initial active micelles and subsequent DOX was achieved by this micelle-in-nanofiber device.
10 Modified tri-axial electrospinning was also combined with drug-loaded lipids to constitute a
11 multilayer and smart drug carrier system for oral drug delivery.^[16b] In a study of Yang *et al.*^[16b],
12 diclofenac sodium/phosphatidyl choline (DS/PL) lipids were entrapped in the core of ES100
13 fibers through tri-axial electrospinning to achieve a pH-stimuli triggered and sustained drug
14 release. This proof-of concept research explored the influence of spinnability of outer-middle-
15 inner solutions on the final fiber structures, and greatly enlarged the selection pool of raw
16 materials. All types of liquid phases could be processed through this modified tri-axial
17 electrospinning, including small molecule solutions and diluted polymer solutions, which were
18 un-spinnable in the traditional electrospinning.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

45 In addition to the polymer nanospheres, mesoporous bioactive glass nanoparticles (MBNs)
46 were also regarded as superior drug carriers to prolong the drug release due to the high surface
47 volume ratio for absorbing biomolecules. Kang *et al.*^[122] incorporated fibroblast growth factor
48 2 (FGF2) and fibroblast growth factor 18 (FGF18)-loaded MBNs into the hollow core of PCL
49 fibers through co-axial electrospinning. FGF2 was designed to dominantly release in the earlier
50 period to promote the cellular angiogenesis and FGF18 was sequentially targeted for **later**
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 osteogenesis. By adjusting the single (PCL shell) or double layer (PCL shell and MBNs) of
 2 barriers, the sustained release patterns can be manipulated as desired.
 3
 4

5
 6 The versatility of electrospun DDS also enable the production of complex and multi-functional
 7 implants possible. Liu *et al.*^[62] fabricated a uniformed mixed membrane consisting of
 8 hyaluronic acid fibers and collagen fibers by simultaneously running two electrospinning
 9 apparatuses. EGF, pDFG-loaded gelatin NPs, VEGF-loaded gelatin NPs and bFGF were
 10 dispersed into collagen fibers and hyaluronic acid fibers through blend electrospinning,
 11 respectively, forming a composite scaffold with potential to deliver four growth factors in a
 12 stage-wise manner for 30 days. The earlier released bFGF and EGF were responsible for the
 13 epithelialization and vasculature sprouting and the delayed release of pDFG and VEGF were
 14 aiming for blood vessels maturation.
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31

32 **Table 6. Representative electrospun DDS *via* combinational-drug incorporation approaches**
 33 **and the associated highlights and applications.**
 34
 35

Materials	Drugs	Highlights	Applications	Ref.
PLGA	Rg3, PEG-NH ₂ , RGD and bFGF	Combination of blend electrospinning and surface functionalization; Sustained release of Rg3 for 40 d; Combination of the wound healing and inhibition of hypertrophic scars formation.	Wound healing	^[29d]
PCL (shell)	PVP/BSA/rhTGF-β1 (core) BMSC-E7 (surface)	Combination of co-axial electrospinning and covalent surface functionalization; Dual drug release: burst release of rhTGF-β1 in 5 d, and sustained release for 22 d; E7 on the PCL shell significantly promoted BMSC initial adhesion.	Cartilage tissue engineering	^[63]
PCL-PEG copolymer	BMP-2-loaded BSA	Combination of drug-loaded BSA nanoparticles with blend electrospinning;	Bone tissue engineering	^[65]

	nanoparticles and dexamethasone	Dual-drug release in a sequential manner: initial dexamethasone release in 8 d and sustained release of BMP-2 up to 35 d.	
PCL (shell) and PEO(core)	FGF2 and FGF18-loaded MBNs	Combination of drug-loaded MBNs, blend and co-axial electrospinning; Dual growth factors up to 65 d in sequential manner: fast release of FGF2 and sustained release of FGF18.	Bone tissue engineering ^[122]
Cross-linked gelatin (shell)	DOX-loaded FA decorated micelles and PVA blend (core)	Combination of drug-loaded micellar system with co-axial electrospinning. Burst release of DOX in 20 h and more than 80% of DOX was released in 288 h. Delayed release of DOX was achieved by gelatin shell and micelles.	Cancer therapy ^[121]
Chitosan	Gentamicin-loaded liposomes	Gentamicin-loaded liposomes were covalently immobilized onto chitosan fiber surface; Sustained release of gentamicin up to 16 h.	Wound dressing ^[119]
Collagen HA	VEGF-loaded and PDGF-BB-loaded gelatin NPs; bFGF and EGF	Combination of drug-loaded gelatin NPs with blend electrospinning; Programmed, sequential release of four growth factors (burst release of bFGF and EGF; sustained release of VEGF and PDGF-BB) up to 1 month.	Chronic wound Healing ^[62]
PLGA	Paclitaxel and Brefeldin A loaded polymer micelles	Dual-drug release through micelles with blend electrospinning; Burst release of paclitaxel (~60%) and the prolonged release of Brefeldin A (~20%) in the first 96 h.	Cancer therapy ^[123]

Rg3, (20R)-Ginsenoside Rg3; rhTGF- β 1, recombinant human transforming growth factor-b1; BMSC-E7, Bone marrow-derived stem cells specific affinity peptide E7; FGF2, fibroblast growth factor 2; FGF18, fibroblast growth factor 18; FA, folate; PDGF-BB, platelet-derived growth factor BB.

2.3 Drug release kinetics

When released from fibers, drugs go through a cascade of partitioning and diffusion processes within fibers and following dissolution in medium.^[6, 124] In non-degradable fibers, the drug release rate is mainly dependent on water diffusion rate into the matrix, drug diffusion rate out

of the matrix and the drug dissolution rate in the medium, since the average drug diffusion path stays constant. However, in degradable polymer fibers, the polymer degradation rate also plays a key role, because the average diffusion path changes with time.^[125] More specifically, during the fabrication of electrospun DDS, many factors relating to construct, matrix material and drugs can affect the above two-way diffusive process, and thus, influencing the drug release behavior (**Table 7**). Materials, drugs and their interactions will be particular highlighted in the following sections of this review.

Table 7. Possible factors that contribute to the drug release mechanisms ^[7b, 80, 124-126].

Aspect of Construct	Aspect of Material	Aspect of Drug
Geometry	Composition	Drug loading
Dimension	Molecule weight	Drug state
Porosity	Crystallinity	Drug molecule weight
Pore size	Degradation rate	Drug-solubility in medium
Fiber diameter	Swelling ability	
	Drug-polymer interactions	
	Drug distribution within fibers	

2.3.1 Influence of materials

The intrinsic nature of the drug carrier initially determines the drug release duration. When drugs were encapsulated within water-soluble polymers, such as PVA and PVP, they usually achieve full drug release within few minutes or hours.^[10a, 11b] The release rate will be accelerated in electrospun fibers owing to the enhanced solubility.^[10a] The hydrophilicity of natural drug carriers can increase the medium absorption, and thus, enhancing the drug diffusion, leading to rapid drug release. Cross-linking is the main strategy adopted to prolong the drug release in natural polymer fibers.^[127] On the contrary, a hydrophobic polymer matrix with varying degradation rate can extend the release duration to days even months.^[34a, 91-92] The exact release period also relates to the molecular weight, crystallinity and degradation rate of the

biopolymers.^[128] **Table 8** gives few examples of drug release duration of electrospun DDS through blend electrospinning.

Moreover, the feasible blending of polymers provides facile approach to regulate the drug release duration aiming for diverse applications.^[34a] In case of stimuli-responsive materials, DDSs usually show instant drug release upon sensing the stimuli and sustained release in absence of the stimuli.^[41] Nevertheless, when the drugs were located on the surface or near surface vicinity without strong linking, the release duration may show little relevance to the materials nature.^[129]

Table 8. Few examples of drug release duration of electrospun DDS through blend electrospinning.

Polymer	Molecular weight (kDa)	Release duration	Ref.
PVA	67	100% within 60 s ~240 s	[10a]
	31	100% within < 30 s	[10b]
PVP	360	100% within < 1 min	[130]
	1300	100% within ~ 120 min	[11b]
Fish gelatin	-	100% within 4 min	[12]
PCL/gelatin	70 ~ 90 (PCL)	22 d ~ 32d	[31a]
PLLA/PEG	PLLA 50, PEG 2	8 ~14 d	[34a]
PLLA/PEG	100	< 50% over 90 d	[92]
PLA	78	10% ~ 80% over 84 d	[91]
PCL	In-situ synthesis	< 15% over 56 d	[88]
Poly-urethane	In-situ synthesis	< 60% over 91 d	[81]

2.3.2 Influence of drugs and drug-polymer interactions

Drug-type (molecule weight and solubility) and drug loading ratio are two aspects that strongly influence the release kinetics. Pattama *et al.*^[131] thoroughly investigated the drug release behavior of four model drugs, with varying molecule weight and water solubility, from PVA

1 fibers. It was observed that sodium salicylate, which had low molecule weight (160.1 g mol^{-1})
2
3 and high water solubility, reached near 100% of release within few minutes. However, only less
4
5 than 40% of water insoluble indomethacin (357.8 g mol^{-1}) was released over 1400 min. The
6
7 different release tendency was explained by the faster leaching out of matrix in case of low
8
9 molecule weight drugs. In the early studies, Zeng *et al.*^[80] studied the drug release behavior of
10
11 paclitaxel, doxorubicin hydrochloride and doxorubicin base from PLLA fibers. Both PLA fibers
12
13 containing paclitaxel and doxorubicin base showed constant zero-order release, which was
14
15 proportional to the polymer degradation, whereas doxorubicin hydrochloride-loaded fibers
16
17 showed rapid drug release, which was irrelevant to the PLA degradation. It was concluded that
18
19 stable and constant drug release can be acquired when majority of the drugs were embedded
20
21 inside of the fibers by selecting proper lipophilic polymer/lipophilic drug pair and hydrophilic
22
23 polymer/hydrophilic drug pair.
24
25
26
27
28

29 Potrč *et al.*^[129] entrapped hydrophilic ibuprofen and hydrophobic carvedilol into PCL fibers,
30
31 respectively, with loading ratios ranging from 10% to 60%. The dissolution tests indicated that
32
33 all systems exhibited a burst drug release following with a plateau. All fibers in PCL/ibuprofen
34
35 group reached near 100% of release within 6 h; however, only 60–80% of drugs were released
36
37 within 6 h in PCL/carvedilol group. In each group, higher drug loading practically delayed the
38
39 drug release rate to some extent. They also pointed that the delayed release of carvedilol could
40
41 be explained by the high molecular weight of carvedilol and the stronger
42
43 hydrophobic–hydrophobic interactions between matrix and drugs. Similarly, in the study of
44
45 Roman *et al.*^[91], the sustainable release of paclitaxel from PLA fibers were notably delayed by
46
47 the high drug loading ratio. Over 60% of paclitaxel was released over 84 days in PLA fibers
48
49 with a drug loading ratio of 0.25%, vs 30% to PLA fibers with a ratio of 0.58%. However,
50
51 contradictory results were showed in the studies of Xie *et al.*^[24] Varying ratios of tetracycline
52
53
54
55
56
57
58
59

1 and chlorotetracycline were encapsulated into electrospun PDLLA fibers, respectively.

2
3 Increasing the ratio of tetracycline highly accelerated the drug release, whereas increasing the
4
5 ratio of chlorotetracycline significantly decreased the drug release rate. The controversial
6
7 results could be due to the different polymer/drug/solvent interactions occurred.
8
9

10 Above studies relevant to polymer–drug interactions were all conducted in drug-laden fibers
11
12 through blend electrospinning, from which the spontaneous drug distributions completely
13
14 depend on the intrinsic interactions between polymers and drugs. However, through multiple
15
16 modified drug incorporation techniques, drug distributions could be practically manipulated,
17
18 generating programmable drug release behavior.
19
20
21

22 23 24 25 *2.3.3 Influence of drug incorporation techniques* 26

27 As thoroughly discussed in former sections, drug distributions within matrix, which directly
28
29 affect the drug diffusion paths, can be feasibly manipulated through different incorporation
30
31 techniques. **Figure 7** gives a summary illustration of the former discussed techniques and
32
33
34
35
36
37
38
39
40
41

42 **Table 9** further comparatively describe the advantages, limitations and possible drug release
43
44 profiles of each approaches.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59




Figure 7. Schematic illustrations of different drug incorporation techniques *via* electrospinning.

Table 9. Advantages, limitations and possible drug release profiles of different drug incorporation techniques.

Techniques	Advantages	Limitations	Release Trends	Ref.
Surface Immobilization	Avoiding harmful solvents for biomolecules;		Rapid and burst release in case of weak bonding;	[29d, 33a,
	Maintenance of the original physical or degradation properties of matrix;	Cross-linker necessary for long term release;	Sustained release in case of strong covalent bonding;	71c]
Blend Electrospinning	Simple one-step approach;	Possible denaturation of drugs in the harsh organic solvent;	Burst release in case of incompatible drug-polymer interaction;	[10a, 80, 129, 131]

		Uncontrollable drug distribution	Sustained release in case of compatible drug-polymer interaction;	
		Ideal for core-shell structure;	Rapid and burst release in case of hydrophilic and fast-degradable shell;	
		Feasible entrapment of water-soluble or fragile drugs within the core of fibers;	Complex spinnerets configuration;	
	Co/tri-axial Electrospinning	Unspinnable drug solution can be used;	Unsuitable interfacial interactions may cause failure in core-shell structure;	[94-96, 98-99]
		Achievable for dual-drug release;		
		Single one-step approach for core-shell structure;	Emulsion stability need to be well adjusted through surfactants and other emulsification parameters;	[106b, 109, 112, 132]
	Emulsion Electrospinning			
		Ideal for multi-drug release;		[34b, 62, 116-117, 121-123]
	Secondary-carrier and combinational Electrospinning	Feasible combination with extra stimuli-responsive carriers.	Complex system.	
			Achievable for multi-drug and multi-stage drug release.	

Overall, by choosing the appropriate encapsulation approaches, various drugs can be either attached onto the surface, embedded in the surface vicinity, uniformly distributed throughout the whole fibers, or fully confined within the core section of fibers, resulting in rapid, sustained or zero-order drug release profiles. Therefore, when choosing ideal drug release platforms for specific biomedical applications, it is critical to carefully consider both the material/drug

1 composition and the encapsulation technique, which could synergically affect the drug release
2
3 patterns and thus the treatment efficacy.
4
5
6
7
8

9 **3. Applications in Biomedical Fields**

10
11 As discussed above, numerous electrospun scaffolds containing diverse active ingredients can
12 be easily produced through selecting proper materials and approaches. The resultant drug-laden
13 architectures offer massive variations on physical topography, drug loading degree, drug release
14 behavior, and thus, ultimately lead to therapeutic effects, which potentially meet multiple
15 clinical needs. In the current section, the therapeutic outcomes of drug-containing electrospun
16 DDS in some biomedical fields, with a particular focus on tissue engineering and cancer therapy,
17 will be thoroughly discussed below.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

33 **3.1 Simple Drug Delivery Systems**

34
35
36 Due to the high drug loading and high encapsulation efficiency, implantable drug-eluting
37 electrospun fibers have intrinsic advantages over the conventional small-scale drug vehicles as
38 novel drug administration methods through oral, transdermal or ocular routes.^[8, 133] The
39 following sections will summarize the recent endeavors made on these fields and highlight the
40 superiority of electrospun drug formulations.
41
42
43
44
45
46
47
48
49
50

51 *3.1.1 Oral drug delivery*

52
53 Electrospinning technique is able to produce highly porous and fibrous membrane consisting
54 of continuous nanofibers. The highly interconnected porous structure of electrospun fibers
55 allow faster medium penetration, thus resulting in more rapidly dissolving or disintegration of
56
57
58
59

1 the hydrophilic polymers. And the nano-size dimension indicates well dispersible drug particles
2
3 in polymer matrix, causing a great increase of drug solubility.^[7a] These features enable the
4
5 electrospun fibers good candidates for FDDDS of bitter drugs in oral cavity. Samprasit *et al.*^[11b]
6
7 explored the potential of electrospun PVP/cyclodextrin (CD) fibers to deliver meloxicam (MX)
8
9 in oral cavity. This study demonstrated faster disintegration of electrospun PVP/CD fibers than
10
11 the MX powder, commercial tablet and casting films. The optimized and taste-masked
12
13 formulations were non-cytotoxic, physical stable for 6 months in storage condition and all of
14
15 them disintegrated within one minute in simulated moisture environments of oral cavity (**Figure**
16
17 **8a**). Li *et al.*^[10a] investigated the performances of drug-loaded PVA fibers as FDDDS
18
19 formulation and reported that PVA/caffeine and PVA/riboflavin fibrous mats got wetted within
20
21 4.5s and started disintegration within 1.5s.
22
23
24
25
26
27

28 Oral formulations have also been exploited for sustained drug release *via* the sublingual route
29
30 rather than FDDDS. It is an invasive administration and advantageous for the drugs that need
31
32 to be continuously taken-up into the blood circulation. Sharma *et al.*^[15] fabricated an anti-
33
34 diabetic patch by electrospinning of insulin-loaded PVA/sodium alginate (NaAlg) composite
35
36 fibers, from which the insulin was supposed to be released sublingually and absorbed through
37
38 oral mucosa. The *in vivo* experiments conducted by applying the patch below the tongue of a
39
40 diabetic rat. Resultant blood glucose concentration of the diabetic male Wistar rats was
41
42 significantly reduced and the effect lasted for 10 h.
43
44
45
46
47

48 In addition to oromucosal delivery system, electrospun membrane can be further used as oral
49
50 formulations to achieve colon-targeted release. Yang *et al.*^[16b] confined lecithin diclofenac
51
52 sodium (phospholipids PL-DS) within ES100 fibers through co-axial electrospinning to create
53
54 a pH-sensitive drug carrier (**Figure 8b1, 2**). The outer ES100 layer could protect the central-
55
56 located drug from the acid gastric fluid and only started to disintegrate in the neutral pH
57
58
59

environments when the drug carriers reach the colon. Subsequently, partial DS was freed when the DS-loaded lipids were converted to sub-micron sized particles and more DS was continuously released from the lipid particles (**Figure 8b3**). The *ex-vivo* permeation tests indicated highly enhanced colonic membrane permeation ability of fiber dosage compared to free drug. In another study, Jin *et al.*^[44] loaded Gd(DTPA) and indomethacin within the core section of ES100 fibers through co-axial electrospinning to colon-targeted deliver the magnetic resonance contrast agent for imaging diagnosis and therapeutic agents simultaneously (**Figure 8c**).




Figure 8. (a) Images of meloxicam-loaded PVP/CD fibrous mats with different compositions as FDSS in the disintegration tests. Reproduced with permission;^[11b] Copyright 2015, Elsevier B.V. (b) Oral formulation of lecithin diclofenac sodium/ES100 core-shell fibers for colon-targeted drug delivery. (1) SEM and (2) TEM images of the produced core-shell fibers. (3) The proposed drug release mechanism in responsive to neutral and acid conditions. Reproduced with permission;^[16b] Copyright 2016, American Chemical Society. (c) Core-shell fibers to colon-targeted deliver the magnetic resonance contrast agent for imaging diagnosis and

1 therapeutic agents simultaneously. Reproduced with permission;^[44] Copyright 2016, Elsevier
2
3 B.V.

4 5 6 7 8 *3.1.2 Transdermal drug delivery*

9
10 Transdermal drug delivery represents the strategy of drug administration through skin, which
11 is the largest organ in human body.^[134] It has several advantages over hypodermic injections,
12 such as easy accessibility due to the high surface area of skin, less invasive operations required
13 and avoidable hepatic first-pass metabolism.^[135] The drugs can be either absorbed through skin
14 barrier into subcutaneous tissue and systematically taken-up into the blood circle, and then the
15 whole body, or remained locally to treat skin disorders, such as dermatitis or skin cancer, i.e.
16 topical drug delivery.^[135] As the outermost layer of skin, stratum corneum is responsible for the
17 poor drug absorption and only small quantity of drugs can be penetrated into skin. By applying
18 appropriate drug carriers on the skin, long term drug release can be simply achieved.^[134]
19
20 Conventionally, emulsions, creams, gels and transdermal patches are all ideal drug carriers for
21 transdermal drug release.^[18b] Owing to the capability of high drug loading and encapsulation
22 efficiency of electrospinning technique, drug-loaded electrospun membranes are considered as
23 superior options as transdermal patches.
24

25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43 Song *et al.*^[17b] successfully embedded daidzein-loaded lipids into electrospun PLGA nanofibers
44 as transdermal patches to address the problems associated with poor oral absorption and limited
45 bioavailability of daidzine for treating cardiovascular and cerebrovascular disease. A skin
46 permeation enhancer, Azone, was also blended into PLGA matrix to increase the drug diffusion
47 rate by interacting with structured lipids of the stratum corneum. *In vitro* drug release and skin
48 permeation studies showed ~3.8 times higher amount of fiber-released daidzein penetrated skin
49 barrier, compared to the pure daidzein solution. Moreover, better skin retention property was
50
51
52
53
54
55
56
57
58
59

1 observed in case of composite fibers than daidzein-loaded lipids in the long-term period and no
2 obvious skin irritation was observed. More studies have explored the potential of electrospun
3 fibers from diverse polymers as transdermal patches, such as PVP,^[21] PVA/chitosan,^[136]
4 PU/cellulose,^[19] and PVA/Alginate.^[22b]
5
6
7
8
9
10

11 3.1.3 Ocular drug delivery

12 Electrospun patch has been also investigated to deliver drugs into eyes for ocular surface repair.
13
14 Most common clinical substrate for ocular surface repair is human amniotic membrane owing
15 to its biocompatibility, anti-inflammation efficacy and angiogenesis ability.^[137] However, it
16 also has several disadvantages, such as poor mechanical strength, semitransparent appearance,
17 difficulty of handling and the potential risk of disease transmission,^[138] and therefore,
18 alternative choices should be further explored. Compared to bulk material, electrospun patches
19 with micro/nano- size fiber dimensions and high surface area were considered advantageous in
20 topical application or treating the anterior segment eye diseases. Bhattarai *et al.*^[139] fabricated
21 two different dexamethasone-loaded PLA/PVA patches as ophthalmic inserts through either
22 solvent casting or electrospinning method, and further compared the drug release behavior.
23 Results indicated that 90% of the drug was released from the electrospun inserts over 40 h and
24 only 24 h from the solvent-casting inserts. Compared to solvent-casting inserts, electrospun
25 inserts showed more consistent and predictable drug release. In another study of Baskakova *et*
26 *al.*^[140], acyclovir, cyanocobalamin and ciprofloxacin were simultaneously incorporated into
27 PCL fibers to fabricate fibrous matrices as intravitreal implants. Drug release using an *in vitro*
28 eye model showed that the drug residence time (half-life) was extended to 6 days, which was
29 much greater than the small molecule drug solutions, suggesting that the proposed matrices can
30 be a viable option as intravitreal implant. Angkawinitwong *et al.*^[98] encapsulated bevacizumab,
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 a VEGF neutralizing antibody, into the core area in PCL fibers through co-axial electrospinning
2
3 to treat age related macular degeneration. This fibrous solid formulation highly prolonged the
4
5 drug release period over two months, and therefore, reduced the administration frequency and
6
7 avoided the invasive injection in the eyes.
8
9

10 11 12 13 14 15 16 17 **3.2 Tissue Engineering**

18
19
20 Tissue engineering represents a multidisciplinary field integrating the materials, chemistry and
21
22 biological science. Aiming for in-situ tissue regeneration or organ restoration, cells are
23
24 supposed to attach, proliferate and differentiate under the support of the 3D scaffold,s which
25
26 will degrade gradually in the meanwhile.^[141] Another essential link in this strategy is suitable
27
28 biochemical and physicochemical factors that are molecularly affect or guide the cellular
29
30 behaviors. It is well-known that electrospun scaffolds are widely applied as scaffolds for tissue
31
32 regeneration owing to the excellent physical resemblance to ECM. Moreover, increasing studies
33
34 focus on applications of active ingredients-loaded fibrous scaffolds in pursuit of improved
35
36 therapeutic outcomes. Their achievements made on regeneration or restoration of multiple
37
38 organs, such as skin, bone, cartilage, muscle, tendon, heart, nerve and blood vessels, are
39
40 discussed in this section.
41
42
43
44
45
46
47
48

49 *3.2.1 Wound healing and skin tissue regeneration*

50
51 Wound healing is a dynamic and interactive process involving dermal cells (e.g., fibroblasts,
52
53 endothelial cells), growth factors (e.g., EGF, FGF-2, and VEGF), cytokines, etc. Four periods
54
55 consisting of hemostasis, inflammation, proliferation and remodeling/maturation are included
56
57
58
59

1 in this process.^[142] As described above, the high porosity and surface area enable electrospun
2 structure an optimal candidate to fulfill the mission of conventional wound dressings, such as
3 being permeable to moisture and oxygen, protecting the wound from microbes and mechanical
4 irritation and allowing the exudate removal.^[143] Additionally, the high resemblance to ECM
5 and feasibility for multifunctionalization make electrospun drug-loaded scaffolds prospective in
6 treating skin trauma and disorders, especially for some chronic skin diseases which have no
7 clinical cures yet.

8 Antibacterial property is the primary function required for a wound dressing material and it can
9 be easily achieved by incorporating antibiotics,^[90, 144] antibacterial peptide motif^[78] and
10 antibacterial nanoparticles,^[33c] into electrospun membranes. For instance, tetracycline
11 hydrochloride was loaded into PCL/cellulose acetate/dextran and PVA/chitosan composite
12 membranes to facilitate wound healing, respectively.^[144] The obtained membranes were proved
13 to be biocompatible and bioactive, and effectively antibiotic against bacterial. An antimicrobial
14 peptide motif (Cys-KR12) was immobilized onto electrospun silk fibroin nanofiber surface
15 through EDC/NHS and thiol-maleimide click chemistry by Song *et al.*^[78] In addition to the
16 antibacterial efficacy, the immobilized Cys-KR12 further promoted the proliferation of
17 keratinocytes and fibroblasts and the differentiation of keratinocytes, and also inhibited the
18 inflammatory cytokine expression.

19 Apart from the feasible implementation in acute infections of wound sites, electrospun scaffolds
20 are able to sustainably release therapeutic agents and simultaneously support in-situ tissue
21 regeneration for curing chronic wound diseases, such as diabetic wound diseases.^[62, 103, 145]
22 Various drug-loaded scaffolds were designed to improve the poor angiogenesis and delayed
23 wound closure in diabetic wounds associated with high blood glucose level, and therefore to
24 achieve accelerated diabetic wound healing. Lai *et al.*^[62] co-loaded multiple angiogenic factors

1 (VEGF, bFGF, PDGF and EGF) into collagen/hyaluronic acid composite scaffolds to rapidly
2
3 increase the blood vessels formation and further allow fast integration with surrounding tissues.

4
5 An examination on *in vivo* streptozotocin (STZ)-induced diabetic rats model confirmed
6
7 increased vessel density and lumen area, elevated collagen deposition and subsequent
8
9 accelerated wound closure rate. Other angiogenic agents, such as epigallocatechin-3-O-gallate
10
11 and desferrioxamine, were also loaded into hyaluronic acid/PLGA and PVA/chitosan scaffolds,
12
13 respectively, to dramatically increase the neovascularization and collagen deposition, and thus,
14
15 promote the diabetic wound healing.^[103, 146]
16
17

18
19 Ren *et al.*^[145b] developed a composite scaffold consisting of both beneficial micro/nano
20
21 structural cues and chemical active agents to create a synergistic microenvironment for rapid
22
23 diabetic wound healing (**Figure 9**). It was observed that nanopores enhanced the protein
24
25 adsorption, and **thus**, the cellular adhesion and proliferation, and the aligned fibers favorably
26
27 regulated the endothelial cellular angiogenesis differentiation. 0%, 5%, 10% and 15% of
28
29 dimethyloxalyglycine (DMOG)-loaded MSNs (PL, 5 DS-PL, 10 DS-PL and 15 DS-PL) were
30
31 embedded into aligned PLLA fibers with nanopores on the surface for sustained release of both
32
33 DMOG and Si ions, which both have positive effects on the angiogenesis of endothelial cells.
34
35 As shown in **Figure 9a**, drug-loaded MSNs were uniformly distributed throughout the aligned
36
37 PLLA fibers with interconnected nanopores and varying ratios of DMOG and Si ions can be
38
39 stably released over 360 h (**Figure 9b,c**). An *in vivo* study of placing the 10% of DMOG-
40
41 MSNs/PLLA fiber meshes onto wound regions in the diabetic mice proved that drug-loaded
42
43 fiber meshes significantly enhanced the wound healing ratios (97%) after 15 days of treatment,
44
45 compared to undressed wounds (84%) (**Figure 9d, e, f**).
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




Figure 9. (a) SEM images of the aligned porous electrospun membranes with increasing drug ratios. The corresponding TEM image inserted in each SEM images. (b) DMOG and (c) Si ion release profiles. (d) Overview of the size change of the large excision wounds made in the dorsal skin of diabetic mice (control, PL and 10 DS-PL) at 0, 7, 11, 13, 15 day post-surgery. (e) Traces of wound bed closure for each treatment group *in vivo*. (f) Statistical analysis of wound area.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. Reproduced with permission;^[145b] Copyright 2018, Elsevier B.V.

Studies focusing on the other aspects of wound healing were also reported. Cheng *et al.*^[29d] encapsulated a bioactive drug 20(R)-ginsenoside RG3 onto PLGA fibers through pDA coating, and then further immobilized bFGF onto fibers surfaces to inhibit the formation of hypertrophic scars during wound healing process. Dong *et al.*^[147] created a handy electrospinning device to

1 fabricate antibacterial PCL membranes, which reduced the inflammation and promoted the
2
3 wound healing *in vivo*. This convenient handy device holds great potential to meet the clinical
4
5 needs in emergency medical transport, hospitals, or first aids at home.
6
7

10 3.2.2 Musculoskeletal tissue regeneration

11 Musculoskeletal tissues play a vital role to offer physical support and allow stable movement
12
13 of human body and could extend to bone, skeletal muscle, and connective tissues, e.g. tendon,
14
15 cartilage and ligament.^[148] The disease and injury related to musculoskeletal tissues can be
16
17 acute bone or muscle trauma, or chronic osteoarthritis, rheumatoid arthritis and degenerative
18
19 disc disease.^[148a] Large bone defects and severe injuries in muscles and connective tissues (i.e.
20
21 cartilage, tendon and ligament) have low intrinsic healing capacity due to the lack of
22
23 vascularization and poor blood supply.^[149] Tissue engineering appeared as an innovative and
24
25 promising strategy to endow the in-situ regeneration ability to these severe defect sites. The
26
27 produced fibrous scaffolds are usually applied in musculoskeletal tissue regeneration in two
28
29 approaches. Firstly, 3D structural scaffolds are implanted to maintain the geometrical integrity
30
31 of the target tissue and provide the necessary support for cells to attach, proliferate and
32
33 differentiate in the meanwhile.^[150] Another method is preparing and utilizing occlusive
34
35 membranes for providing space maintenance, covering the diseased area, promoting the
36
37 recruitment and growth of osteogenic cells and blocking the migration of competing soft tissue
38
39 cells from overlying mucosa.^[77, 151]

40
41
42 Incorporation of small molecules or single growth factor is one of the simplest way to load
43
44 therapeutics into scaffolds for better performances. For better skeletal muscle regeneration, Liu
45
46 *et al.*^[152] coated PCL fibers with mussel-inspired poly-norepinephrine (pNE), a catecholamine
47
48 functioning as a hormone and neurotransmitter in the human brain, to obtain fiber surfaces
49
50
51
52
53
54
55
56
57
58
59

1 enriched with catechol groups that attract primary amine or thiol-based biomolecules. Their
2 study revealed that fiber meshes with thinner fiber diameter could be more effectively
3 functionalized by pNE, and thus had higher muscle cell proliferation and adhesion and
4 treatment efficacy for repairing impaired musculus rectus abdominis in a rat muscle injury
5 model. In the study of Pauly *et al.*,^[153] connective tissue growth factor (CTGF) was conjugated
6 onto longitudinally aligned PCL fiber bundles to mimic the hierarchical structures of native
7 human anterior cruciate ligament (ACL) for ACL regeneration. CTGF was sustainably released
8 over 2 weeks, evidenced by an ELISA assay. Elongated cells along the longitudinal axis fully
9 covered the fiber bundles after 7 days, and significant collagen deposition specific for ligament
10 tissue was observed on CTGF-loaded fiber bundles after 21 days of *in vitro* cell culture, which
11 was further confirmed by the *in vivo* subcutaneous implantation tests. For repairing cartilage
12 defects in osteochondral injuries, Liu *et al.*^[115] constructed platelet-rich plasma (PRP)-loaded
13 PCL scaffolds to obtain co-delivery of multiple therapeutic agents. Abundance of growth
14 factors derived from PRP, such as PDGF, TGF- β and IGF, were simultaneously released from
15 the porous scaffolds over 30 days. Highly enhanced gene expression of collagen-II, aggrecan
16 and SOX9 suggested beneficial chondrogenesis of BMSCs when cultured on PRP containing
17 scaffolds. The *in vivo* healing efficacy was evaluated by implanting the scaffolds in a New
18 Zealand rabbit model with full-thickness cartilage and subchondral bone defect. The cartilage
19 defect was nearly filled with regenerated tissues with glossy and normal articular surface
20 12 weeks after the surgery, while there was still a gap to be filled in the pure PCL scaffolds group.
21 Tendon tissues mainly constituting of parallel collagen fibrils work as an intermediate
22 connector between the bone and muscle to achieve stress transfer and joint stability.^[154]
23 Although aligned fibers have been reported to promote tenogenesis, it is not enough for teno-
24 differentiation of stem cells.^[155] Zhang *et al.*^[92] encapsulated small molecule Trichostatin A

(TSA), an histone deacetylases inhibitor, into aligned PLLA nanofibers to commit teno-differentiation of stem cells for tendon tissue regeneration. Comparative *in vitro* tendon stem/progenitor cell culture studies on random fibers and pure polymer fibers, displayed highly elevated tendon-associated genes expression and collagen accumulation in groups with both aligned topography and TSA entrapment, which could be further verified by the enhanced neotendon formation in an *in vivo* Achilles tendon repair model. Adhesion formation associated with fibroblast adhesion and proliferation is the major clinical complication in tendon healing after tendon surgery, and it could severely affect the joint movement. To eliminate the risk of adhesion formation, Zhao *et al.*^[114] prepared core-shell hyaluronan/PLLA fibrous scaffolds with mitomycin-C (MMC) embedded in the core area of fibers, since MMC was reported to prevent the adhesion formation without impairing the tendon healing process (**Figure 10a**). The obtained fibrous membrane was designed to act as a physical barrier to mediate apoptotic gene expression and inhibit collagen expression in adhesion tissues. *In vitro* drug release study showed sustained release of MMC up to 40 days (**Figure 10b**), which efficiently inhibited the survival, adhesion and proliferation of fibroblasts. The healing efficacy were evaluated in both animal models of rabbit flexor digitorum profundus (FDP) tendon and rat Achilles tendon (**Figure 10c, d**). Severe adhesions were observed in the untreated control group in both models, and groups treated with PLLA-only membranes generated small bundles of fibrous tissues, connecting the tendon with surrounding tissues. Very little adhesion was observed in the repaired tendon and the peritendinous tissue when treated with MMC-loaded PLLA membranes in both models. This gross observation was further confirmed by the following histological analysis (**Figure 10c2, d2**). Consequently, the adhesion scores and grades for the histological tendon adhesions of the drug-loaded groups were both significantly lower than the control and PLLA-alone group (**Figure 10e, f**). This dramatically inhibition of adhesion formation was

further explained by the identification of the up-regulation of apoptotic protein Bax expression and down-regulation of proteins Bcl2, collagen I, collagen III and α -SMA during the healing process with minimum adhesion formations. Overall, the proposed scaffolds were considered to be highly prospective as anti-adhesion materials in tendon tissue regeneration.





Figure 10. (a) Cumulative release and (b) daily release of MMC from electrospun PLLA-MMC fibers (1 and 4% of MMC in MMC1 and MMC2). (c1 and d1) Gross evaluation of the rabbit FDP tendon and rat Achilles tendon model in control, PLLA and PLLA-MMC2 groups. HE (c2 and c3) and Masson (d2 and d3) staining of control, PLLA and PLLA-MMC2 groups. T, tendon; M, membrane. 21 days after surgery, tendon repair and peritendinous adhesions were assessed by macroscopic evaluation of tendon adhesions (e1 and f1), and histological adhesion

1 grade (e2 and f2). * $P < 0.05$ compared with control group; § $P < 0.05$ compared with PLLA
2
3 group. Reproduced with permission;^[114] Copyright 2015, Elsevier B.V.
4
5
6
7

8 Biomaterials-associated bone tissue engineering refers to the construction of an artificial
9
10 implant which can accelerate bone vascularization and mineralization, therefore resulting the
11
12 reconstruction of injured or diseased bones.^[77, 118, 151] Kang *et al.*^[122] proposed a novel
13
14 therapeutic design which embedded and delivered two growth actors simultaneously in core-
15
16 shell fibers in combination of mesoporous bioactive glass nanospheres (MBNs), which acted
17
18 as drug carriers and meanwhile enhanced the apatite-forming ability and mechanical properties
19
20 of the scaffolds. FGF18-loaded MBNs and FGF 2 were co-encapsulated into the core section
21
22 of PCL/PEO fibers to achieve an earlier release of FGF2 for cell proliferation and angiogenesis
23
24 and later release of FGF18 for osteogenesis. Both growth factors were sustainably released over
25
26 65 days owing to the protective PCL shell. *In vitro* rat mesenchymal stem cells study presented
27
28 significantly increased cell proliferation, ALP activity and expression of bone-related genes
29
30 (Col I, ALP and OPN) and cellular mineralization on the composite fibrous scaffolds. When
31
32 implanted in rat calvarium defects for 6 weeks, FGF2/FGF18 loading substantially increased
33
34 the hard tissue ingrowth regions, which was evidenced by the highly increased bone volume
35
36 and bone surface density from micro-CT images. In the study of Weng *et al.*^[156], ultralight 3D
37
38 fibrous aerogels composed of electrospun PLGA/collagen/gelatin fibers and Sr–Cu co-doped
39
40 bioactive glass fibers were constructed by combining electrospinning and freeze-drying
41
42 methods for cranial bone defect healing (**Figure 11a**). Heptaglutamate E7 domain specific
43
44 BMP-2 peptides were further conjugated onto the optimized scaffolds for osteoinductive feature.
45
46 *In vitro* release study suggested that 90% of the peptide was released within the first week
47
48 followed by sustained release up to 4 weeks (**Figure 11b**). The sustainably released E7-BMP-
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 peptide and bioactive ions (Ca^{2+} , Si^{4+} , Sr^{2+} and Cu^{2+}) from bioglass fibers can work
2 synergically to enhance bone healing and defect closure as the *in vivo* results showed an almost
3 3-times higher (20 mm^3 *v.s.* 7 mm^3) regenerated bone volume in comparison to non-peptide
4 group after treatment for 8 weeks (**Figure 11c**). Moreover, μ -CT images were used to
5 quantitatively confirm that the high- density bone mineral covered more than half of the cranial
6 defect after 8 weeks in E7-BMP-2-loaded group.
7

8 Electrospun scaffolds displayed favorable advantages in musculoskeletal tissue regenerations
9 that required intensive vascularization and possible specific configuration, such as alignment.
10 Co-loading of multiple therapeutic agents could efficiently enhance the treatment efficacy and
11 avoid the side effects maximally. Specifically for bone tissue regeneration, vascularization and
12 further mineralization could be both achieved by co-loading of angiogenic factors and bioactive
13 agents that induced biomineralization. Moreover, large volume scaffolds that closely mimic the
14 native tissue and organs could be feasibly created by combining electrospinning and other
15 fabrication techniques. Nevertheless, the produced scaffolds still have limited applications in
16 high load-bearing bones and long-term degradation profiles were still missing in most of the
17 studies.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



36 **Figure 11.** (a) Schematic illustration on the formation of the 3D hybrid nanofiber aerogel and
37 its structure at different length scales. (b) Loading of E7-BMP-2-FITC peptide on 3D aerogels
38 and their cumulative release. (c) Representative planar radiographs of cranial bone defects at 4
39 and 8 weeks after implantation: (c1/c4) No treatment (4w/8w). (c2/c5) 3D aerogel group
40 (4w/8w). (c3/c6) Peptide-loaded aerogels group (4w/8w). Reproduced with permission;^[156]

41 Copyright 2018, John Wiley and Sons.

42 3.2.3 Cardiac tissue engineering

43 Cardiovascular diseases such as myocardial infarction (MI) or progressing heart failure have
44 become the major cause of morbidity and mortality world widely.^[157] Developing therapies that

1 induce regeneration or prevent degeneration of myocardial tissue after MI is highly clinically
2 relevant since cardiac tissues have limited regenerative capacity and the possibility to self-
3 renew and restore is rare.^[158] The strategies of cardiac tissue regeneration have come up in two
4 related directions: *in vitro* engineering and maturation of cardiac tissues followed by
5 implantation, and development of methods for controllable drugs/siRNA/protein delivery into
6 the heart.^[159] Related to electrospun cardiac patches, earlier reports have emphasized on the
7 mimicking of structural, mechanical and conductive properties of native cardiac tissues, aiming
8 to facilitate the *in vitro* adhesion and maturation of cardiovascular cells.^[160] Currently,
9 combinational implementations of the two aspects, i.e., tissue regeneration and drug delivery,
10 emerged as prospective approaches to achieve full recovery of the dysfunctional myocardium.
11 It is well known that many growth factors and cytokines, such as VEGF and bFGF, are highly
12 implicated in cardiomyocytes proliferation and survival and the maintenance of cardiac
13 function.^[161] However, their clinical uses were severely restricted by the fast
14 degradation/elimination from the biological environment. Drug-loaded electrospun cardiac
15 patches were thus expected to achieve sustained release in local area and further help restore
16 the myocardium function. Lakshmanan *et al.*^[87] embedded two angiogenesis growth factors
17 (VEGF and bFGF) into a blend polymeric scaffold to promote vascularization for functional
18 cardiac regeneration. The encapsulated VEGF and bFGF were sustainably released over 300 h
19 and efficiently rescued cells from hypoxic stress for both *in vitro* chemical hypoxia model and
20 *in vivo* ischemic model. In an acute *in vivo* rabbit acute myocardial infarction (AMI) model, the
21 dual-growth factor releasing patches accelerated neovascularization and functional recovery of
22 the ischemic heart. In another study, VEGF was confined within PCL/gelatin fibers through co-
23 axial electrospinning, resulting a sustained release over 21 days.^[162]

1 Gene therapy was combined with electrospun patches as well to explore the potential to remodel
2
3 dysfunctional heart tissues after MI. Gu *et al.* [68] incorporated recombinant adeno-associated
4
5 virus (AAV) vectors into PEUU and PEEUU fibers by both blend and co-axial electrospinning
6
7 methods (**Figure 12a**). AAV encoding green fluorescent protein (GFP) from co-axial fibers can
8
9 be stably released over 2 months (**Figure 12b**). After implantation in the rat left ventricular
10
11 lesions after MI, the fibrous cardiac patches exhibited extensive cellular infiltration and the
12
13 AAV-GFP-loaded patches showed higher gene expression compared to the AAV-alone
14
15 injection without support and patches without AAV (**Figure 12c**). In addition, both α -SMA and
16
17 cardiac troponin T positive cells could be successfully transduced by the cardiac patch
18
19 containing AAV, proving improved cardiac function and remodeling.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




Figure 12. (a) SEM images and schematic illustrations on AAV encapsulation strategies of different scaffolds. (1) Cross section, scale bar, 10 μm; (2) surface, scale bar, 20 μm. (b) Release profiles of AAV DNA from scaffolds. * $P < 0.05$ compared with PEUU solid fibers. (c) Representative composite views of cross-sections of infarcted rat hearts harvested at 12 weeks, and stained by Masson's trichrome for (1) direct injection of AAV9-cmv-GFP, (2) PEEUU group, and (3) PEEUU/AAV9-cmv-GFP group. Yellow dashed lines trace the implanted

1 material areas. Scale bars, 2 mm. Reproduced with permission,^[68] Copyright 2017, Elsevier
2
3 B.V.

4
5
6
7 Another key aspect of mimicking the native myocardium is to mimic the conductive properties,
8
9
10 which are responsive for coordinated propagation of electrical signals to produce synchronous
11
12 contractions that pump blood forward.^[163] Conductive materials, such as carbon nanotubes
13
14 (CNTs) and polyaniline (PANI), were incorporated as the “therapeutic agents” in these cases to
15
16 form the conductive network in the scaffolds.^[160d, 164] Liu *et al.*^[164] loaded up to 6% of CNTs
17
18 into highly aligned PEG-PLLA copolymer (PELA) fibers through both blend and co-axial
19
20 electrospinning. *In vitro* cardiomyocytes culture indicated that scaffolds containing higher
21
22 ratios of CNTs could favorably maintain the cell viabilities, induce the cell elongation,
23
24 accelerate the production of sarcomeric α -actinin and troponin I, and enhance the synchronous
25
26 beating of cardiomyocytes. By comparing the blend and core-shell fibers, they concluded that
27
28 core-shell fibers with 5% of CNTs could beneficially support the cardiomyocyte proliferation
29
30 with a generation of organized contractile proteins and a pulsation frequency close to that of
31
32 the atrium without external electric stimulation. Similarly, Wang *et al.*^[160d] blended up to 3 wt%
33
34 of PANI into PLA fibers to construct fibrous nano sheets with improved electrical conductivity
35
36 and enhanced cardiomyocytes maturation and spontaneous beating for cardiac tissue
37
38 regeneration and cardiomyocytes-based 3D bioactuators.

39
40
41
42 A recent study firstly reported the electrospinning of decellularized porcine cardiac ECM to
43
44 fabricate well-defined cardiac scaffolds, which preserved the unique collagenous composition,
45
46 microstructure, mechanical performances, bioactivity, and biocompatibility of cardiac
47
48 ECM.^[165] However, other functions such as electrical conductivity have not been explored yet.
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

1 between synthetic scaffolds and native ECM by integrating multiple functions into the well-
2 defined cardiac scaffolds for better resemblance.
3
4
5
6
7

8 3.2.4 Nerve tissue regeneration 9

10 The application of electrospun scaffolds extends to both peripheral nerve injury,^[76, 88, 101, 166]
11 and central nervous system injury,^[28a, 167] which consists of traumatic brain injury^[168] and
12 spinal cord injury.^[33b, 91, 169] Those neurodegenerative diseases and traumatic nerve injuries
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


vastly deteriorate the life quality and proper treatment methods are yet missing. As the nerves have limited capacity to spontaneously regenerate after traumatic injury, innovative strategies are being perused to promote the functional repair. The standard treatment can be summarized as "support and therapeutic", which is the combination of localized delivery of therapeutic molecules along with specialized architectures to support axonal growth and conformal repair.^[170] Earlier studies have already demonstrated that micro- and nano-scale fibrous substrates could enhance neurite outgrowth,^[171] neuronal maturation,^[172] and neuronal differentiation.^[173] And aligned fibers could guide the neuron cells to elongate along the major axis and form orientated cellular morphology.^[166a, 174] Furthermore, drug-loaded electrospun scaffolds can function as both the drug carriers and the protective dressings for nerve systems, and then beneficially facilitate the neural tissue repair.

Suzuki *et al.*^[88] studied the capacity of electrospun PCL membrane to continuously deliver methylcobalamin to the peripheral nerve injury site for nerve regeneration. Evidenced by the *in vitro* drug release and *in vivo* rat sciatic nerve crush injury model, sustained release of methylcobalamin over 8 weeks sufficiently promoted the recovery of the motor and sensory function, the recovery of nerve conduction velocity, and the promotion of myelination. Naseri-Nosar *et al.*^[175] produced a fibrillated cellulose acetate (shell)/PLA (core) scaffolds and then

1 coated with citalopram-loaded gelatin nanoparticles. The citalopram-releasing scaffolds were
2
3 further implanted in a rat sciatic nerve defect model to evaluate the potential for neural
4
5 regeneration. The sciatic functional index (SFI) value corresponding to the drug releasing
6
7 scaffolds was -34.23 ± 4.15 at 60th days, whereas -55.03 ± 3.16 for blank scaffolds, implying
8
9 the significantly promoted treatment progress through immobilization of drug-loaded
10
11 nanoparticles.
12
13

14
15 In addition to the small molecular drugs, biomacromolecules such as growth factors and
16
17 peptides were also proved beneficial to the adhesion, expansion and maturation of neural cells.
18
19 Li *et al.*^[33b] embedded stromal-cell-derived factor-1 α (SDF1 α) in radially aligned collagen/PCL
20
21 fibermats to provide directional cues, i.e., alignment topography and biological gradients, for
22
23 recruitment of neural stem cells from the central canal region to the lesion site to repair spinal
24
25 cord injury. A collagen-binding domain (CBD) was conjugated onto SDF1 α for stronger
26
27 binding to collagen, resulting in gradient and sustained release of SDF1 α over 7 days. The
28
29 gradient distribution of chemokine SDF1 α and the radical aligned topography both contributed
30
31 to the elongation of cells along the radical direction and highly accelerated cell migration from
32
33 periphery towards center area. The produced materials were proved to be solid matrices for
34
35 neuronal cell migration, differentiation and axonal outgrowth as well as bridges to guide axons
36
37 extension to establish functional connections. Zhang *et al.*^[101] loaded nerve growth factor
38
39 (NGF) into conductive composite scaffolds through co-axial electrospinning, and further
40
41 studied and assessed the synergistic **effects** of electrical stimulation and NGF on the neuron
42
43 growth. It was found that the aligned structure, electrical stimulation and NGF release all
44
45 stimulated PC12 cell differentiation and contributed to the enhanced neurite outgrowth of PC12
46
47 cells.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 Aiming for bridging the defected nerve with a gap larger than 10 mm, Zhu *et al.* [76] produced
 2 a tubular PCL nerve conduit composed of electrospun microfibers. Peptide self-assembled
 3 RGD and YIGSR layers were non-covalently bonded to the obtained PCL fibers and were
 4 expected to improve the biocompatibility of hydrophobic PCL fibers (**Figure 13a, b**). *In vitro*
 5 cell culture demonstrated that RGD and YIGSR synergistically enhanced the cellular
 6 proliferation and neurite outgrowth. Sciatic nerve defects were surgically created on adult male
 7 Sprague-Dawley rats and then sutured with surface-modified PCL conduits to evaluate the *in*
 8 *vivo* axonal regeneration (**Figure 13c**). The morphometric analysis of the harvested nerves after
 9 12 weeks displayed that the PCL conduits with RGD/YIGSR coating exhibited equivalent and
 10 comparable healing effect to auto grafts regarding the total area of regenerated axons, the total
 11 number of myelinated axons, and the diameter of myelinated axons. By comparing with the
 12 RGD-only and YIGSR-only group, they concluded that the co-existence of RGD and YIGSR
 13 synergistically promoted axonal regeneration and contributed to greater neurologic functional
 14 recovery.



1 **Figure 13.** (a) Structure characterization of PCL and peptide modified PCL tubular grafts: (1)
 2 Optical image and (2) SEM images for the cross-section. Fluorescence microscopy image of
 3 cross-section of tubular scaffold and film scaffold for (b1, 4) FITC-labeled PCL-RGD; (b2, 5)
 4 cross-section of tubular scaffold and film scaffold for (b1, 4) FITC-labeled PCL-RGD; (b2, 5)
 5 rhodamine-labeled PCL-YIGSR; (b3, 6) both FITC-labeled RGD and rhodamine-labeled
 6 rhodamine-labeled PCL-YIGSR; (b3, 6) both FITC-labeled RGD and rhodamine-labeled
 7 YIGSR together. (c) The gross view of the regenerated nerve, toluidine blue staining of
 8 regenerated axons, TEM of regenerated axon, and myelin sheath at middle portion in all groups
 9 at 12 weeks after surgery: (c1, 6, 11, 16) autograft group, (c2, 7, 12, 17) control group, (c3, 8,
 10 13, 18) RGD group, (c4, 9, 14, 19) YIGSR group, and (c5, 10, 15, 20) RGD/YIGSR group.

11 Reproduced with permission;^[76] Copyright 2017, John Wiley and Sons.

12 Besides traditional drugs and biomolecules, novel materials such as graphene oxide were
 13 employed in nerve tissue engineering as well.^[176] Directional guidance, inherent regulation *via*
 14 biomolecules and synergy effects from multiple factors are the main themes of the current
 15 research in nerve tissue engineering. However, matched biodegradation profiles of scaffolds
 16 were mostly missing though intensive studies have focused on the grafts fabrication and *in vitro*
 17 and *in vivo assays*.

32.5 Blood vessel regeneration

33 Cardiovascular diseases, such as coronary artery and peripheral vascular diseases still remain
 34 as the prevalent cause of death due to the continued growing of aged population world widely.

35 [31b, 33a, 72] Artificial vascular grafts to replace diseased or narrowed vessels have been
 36 recognized as the clinical focus owing to the limited donation of autologous vessels. Although
 37 commercial products such as Dacron and Teflon have been successfully applied as large
 38 diameter (> 6 mm) vascular grafts with high blood flow, acute thrombus formation and intimal

1 hyperplasia could be initiated in case of small diameter vascular grafts (SDVGs) (< 6 mm), by
2
3 the surface thrombogenicity and low compliance of Dacron and Teflon.^[177] The development
4
5 of SDVGs is still clinically necessary. In recent years, electrospun fibrous scaffolds were
6
7 intensively investigated to fabricate SDVGs due to its feasibility for generating a tubular and
8
9 porous structure by collecting on a rotating mandrel. Moreover, the electrospun scaffolds can
10
11 be easily functionalized to meet the clinical requirements for SDVGs, for instance, to prevent
12
13 thrombosis, to inhibit hyperplasia (over-proliferation of smooth muscle cells) and to promote
14
15 rapid endothelialization for vascular regeneration.^[33a, 81]

16
17
18 Punnakitikashem *et al.*^[81] produced multifunctional tubular BPU scaffolds containing
19
20 dipyridamole to achieve full generation of small diameter vessels since dipyridamole was
21
22 reported to not only inhibit the thrombosis formation and over-proliferation of smooth muscle
23
24 cells, but also promote and stimulate the proliferation of vascular endothelial cells. The
25
26 sustained release of dipyridamole extended to 91 days, which effectively increased the human
27
28 blood clotting time, reduced the human platelet deposition, inhibited the human aortic smooth
29
30 muscle cell proliferation and finally improved the proliferation of human aortic endothelial cells.
31
32 Surface modification, such as heparin immobilization, represents another crucial strategy to
33
34 functionalize the tubular fibrous scaffolds for SDVGs regeneration.^[33a, 72, 178] In the study of
35
36 Yao *et al.*^[33a], heparin was immobilized onto PLC/chitosan electrospun fibers through ionic
37
38 bonding, resulting in stable release over 37 days to improve the hemocompatibility. When
39
40 implanted in rat abdominal aorta for 1 month, the scaffolds showed well anti-thrombogenic
41
42 effect and enhanced in-situ endothelialization. Qiu *et al.*^[72] immobilized heparin onto
43
44 polycarbonate-urethane (PCU) fibrous scaffolds with plasma-treated fiber surface (**Figure 14a**).
45
46 It was found that plasma treatment could more effectively introduce amine groups for
47
48 subsequent heparin conjugation, in comparison to other methods, such as aminolysis or physical
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 adsorption. The patency of heparin-conjugated PCU grafts was testified by implanting in the
2
3 left common carotid artery of Sprague-Dawley rats. As shown in **Figure 14b**, more visible
4
5 microvessels can be observed around the heparin-coated grafts harvested after both 2 and 4
6
7 weeks *in vivo*, indicating enhanced vascularization. More SMA+ cells migrated through the
8
9 outer layer of PCU-heparin grafts, suggesting promoted cell infiltration (**Figure 14c**). The
10
11 patency, early stage of endothelialization and graft integration were dramatically improved by
12
13 heparin conjugation.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65




Figure 14. (a) Structural and mechanical characterizations of PCU vascular graft. SEM images of (1) side and (2) top view of an PCU graft. SEM images before and after the plasma treatment in the (3, 5) inner (luminal) and (4, 6) outer surface of the graft. (7) PCU grafts of various inner diameters (1 mm and 6 mm). (8) Bending of a 6 mm-diameter PCU graft. (9) Mechanical characterizations among control (untreated), aminolyzed, polydopamine (PD)-coated, plasma-treated grafts and native common carotid arteries (n = 5). Scale bar = 500 μ m in 1, 2; scale bar

1 = 30 μm in 3, 4, 5, 6. (b) Representative images of graft explantation of control group and
2
3 plasma-treated group after 2 weeks (1, 3) and 4 weeks (2, 4) and patency of the grafts were
4
5 compared in (5). (c) Cross-section immunostaining of PCU plasma-control and plasma-heparin
6
7
8 grafts after 2 and 4 weeks *in vivo*. Immunostaining for SMA (green), cell nuclei (DAPI, blue).
9

10 Scale bar = 100 μm . Reproduced with permission;^[72] Copyright 2017, Elsevier B.V.
11
12
13
14

15 Electrospun scaffolds-based gene therapy was also developed to remedy cardiovascular disease
16
17 in the study of Zhou *et al.*^[66] A bilayer tubular scaffold, consisting of PCL/gelatin fibers as the
18
19 outer layer and miRNA-126 complexes-loaded PELCL fibers as the inner layer, was produced
20
21 through dual-power electrospinning and emulsion electrospinning, respectively. The other layer
22
23 was designed to physically maintain the configuration, and the gene-loaded inner layer was
24
25 expected to regulate the cellular behaviors of vascular endothelial cells. Attributed to the multi-
26
27 barriers in the bilayer scaffolds, miRNA-126 was sustainably released over 56 days. The stably
28
29 released miRNA-126 was proved to highly promote the proliferation of human umbilical vein
30
31 endothelial cells and down-regulate the expression of SPRED-1, which could diminish the
32
33 transmission of intracellular angiogenic signals generated by VEGFs and FGFs. *In vivo*
34
35 examination indicated extensive cell infiltration and highly enhanced ratio of endothelialization
36
37 after implantation of the gene-loaded samples, in comparison to the pure polymer samples. The
38
39 well-preserved miRNA activity and well-maintained patency of bilayer vascular graft
40
41 suggested its prospective application in vascular tissue reconstruction.
42
43
44
45
46
47
48

49 Instead of fabricating a graft for in-situ tissue regeneration, Liu *et al.*^[177] engineered a blood
50
51 vessel graft in *ex vivo* conditions by co-cultivating vascular endothelial and smooth muscle cells
52
53 onto layered electrospun membrane with plasmid DNA encoding bFGF and VEGF integrated,
54
55 which could be further implanted *in vivo* to replace the damaged blood vessels.
56
57
58
59

1 Electrospun fibrous membrane can also found its application in vascular surgery. To prevent
2 vasospasm and repair vascular tissue after vascular surgery, Zhu *et al.*^[34a] produced papaverine-
3 loaded PLLA/PEG scaffolds with adjustable drug releasing rate and degradation period. The *in*
4 *vivo* healing efficiency was certified by warping around the incision sites in the vascular
5 anastomosis of the rabbit neck. After 2 weeks, vessels implanted with drug-loaded PLLA/PEG
6 membranes had no shrinkage in diameter, untraceable hyperplasia and minimized inflammation,
7 compared to PLLA-alone group. Normal vessel morphology with regularly arranged vessel
8 walls were observed on drug-loaded group, indicating great antispasmodic effect and potential
9 to inhibit vasospasm and repair vascular damage.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

25 **3.3 Cancer Therapy**

26
27 Cancer is a leading cause of mortality worldwide. The heterogeneity and adaptive resistance of
28 cancer are the major challenges that are difficult to surmount through traditional chemotherapy.
29
30 The fast-growing nano-medicine technology, which endowed passive or active targeting
31 capacity to cancer cells, can significantly improve the pharmacokinetic profiles of drugs and
32 further enhance the drug accumulation in tumor, offering new strategies to treat cancer.
33
34 Electrospinning has emerged as a highly competitive technology in cancer research, in view of
35 the tunable surface morphology for modulating drug pharmacokinetics and the robust loading
36 capacity for combining various therapeutics.^[59b] A variety of anticancer agents ranging from
37 small molecular drugs to aptamer and RNA can be incorporated into electrospun fibers by
38 simultaneous encapsulation and surface modification, and then undergo a diffusion-controlled
39 or degradation-controlled release profiles depending on the materials and fabricating
40 approaches.^[3b, 179] The traditional approaches for drug loading are summarized in **Table 10**.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

By the virtue of the high surface-to-volume ratio of nanofibers, enhanced local topographic interactions between the substrates and components (e.g., microvilli and filopodia) on cellular surface can also be achieved.^[180] Thus, electrospun scaffolds modified with specific biomarker molecules own great potential for capturing the circulating tumor cells (CTCs) and cancer detection.^[181] Furthermore, compared with other nanostructures, the similarity of the prepared fibers to the collagen fibrils in the ECM can offer better scaffold- and matrix-based 2D or 3D models to enhance the cell–cell and cell–matrix interactions than other nanostructures, which endow the electrospun scaffolds with distinguish advantage in cancer treatment by regulating the cancer cell behaviors.^[182] This resemblance can be further improved by modifying the fibers with ECM proteins or peptides.^[59b, 183] For example, Rabolt *et al.*^[183] found that covalently conjugating perlecan domain IV (PInDIV) peptide onto the electrospun PCL/gelatin composite scaffolds significantly enhanced the adherence and infiltration of metastatic prostate cancer cells towards the electrospun substrates. In this section, we will introduce the recent developments of electrospun scaffolds in the application of cancer research mainly on the cancer therapy and CTCs detection and capture.

Table 10. Recent studies on electrospun scaffolds-based approaches for anticancer drugs and gene delivery.

Anticancer reagents	Polymer matrix	Cancer cell lines	Highlights	Ref.
Camptothecin	PCL	C2C12 cell, <i>in vitro</i>	Sustained release > 6 d; ~ 25% more decrease in cell proliferation than free drugs after 72 h;	[184]
	PLA	HepG2 cell, <i>in vitro</i> and <i>in vivo</i>	20-fold higher cytotoxicity than free drugs after 72 h; More necrosis and apoptosis;	[185]

1	Paclitaxel	PLGA	C6 glioma cells	Sustained release > 80 d;	[186]
2				~ 44% smaller tumors in comparison to free	
3				drug control on day 24;	
4					
5		chitosan/	DU145 prostate	Reduced cell adhesion and proliferation;	[187]
6		HA	cancer cell		
7					
8	Cisplatin	PCL/PG	Lewis Lung	Superhydrophobic;	[59a]
9		C-C18	carcinoma cell	Sustained release in a linear profile > 90 d;	
10				significant increase in median recurrence-	
11				free survival to > 23 d;	
12					
13	Doxorubicin	PEG-	murine mammary	limited injury to neighboring tissue and	[188]
14		PLA	carcinoma EMT6	systemic adverse reactions within 42 d;	
15			cell, <i>in vivo</i>		
16					
17		PEG-	SMMC7721 cell,	Sustained release for 12 d ;	[189]
18		PLA	<i>in vitro</i> and	~ 40% decrease in cell proliferation	
19			hepatocarcinoma	compared with free drugs after 10 d;	
20			H22 cell, <i>in vivo</i>		
21					
22	paclitaxel and	PEG-	C6 Glioma cells	Synergistic inhibition effects on tumor cell;	[190]
23	doxorubicin	PLA			
24					
25	Plasmid DNA	PCL	MCF-7 breast cancer	~40% increase in cell inhibition compared	[191]
26	encoding for		cell	with control scaffold;	
27	Cdk2 shRNA			Sustained release > 21 d;	
28					
29	Paclitaxel and	PLGA	U87MG-luc2 cell	Significant synergistic anticancer effect;	[192]
30	MMP-2 RNAi				

PCL: poly(ϵ -caprolactone); PLA: poly(L-lactic acid)-poly(ethylene glycol); HA: hyaluronic acid; PGC-C18: poly(glycerol monostearate-cocaprolactone); PEG: poly(ethylene glycol); shRNA: short hairpin RNA.

3.3.1 Scaffolds-based drug delivery systems for cancer therapy

As previously mentioned, various anticancer reagents obtained sustained release profile and prolonged activities by encapsulating within electrospun substrates. The fabricated drug-loaded scaffolds can be implanted or injected into the tumor bed after tumor localization.^[193] For instance, Ramachandran *et al.*^[193a] demonstrated that implanting the Temozolomide-loaded PLGA-PLA-PCL fibrous scaffolds into the rat with orthotopic glioma caused long-term (> 4 months) survival of 85.7% of the animals. Wei *et al.*^[193b] injected hydroxycamptothecin-loaded

1 PLA-PEG scaffolds to treat H22-tumor bearing mice and studied the effect of the fiber lengths
2
3 on the biodistribution of fibers in the tumor. They found that longer fiber lengths led to a higher
4
5 tumor accumulation and retention, but less diffusion.
6

7
8 However, two major limitations restricted the clinical application of electrospinning for cancer
9
10 treatment. Firstly, most of the drug release behaviors relied on the passive diffusion, lacking
11
12 the controllability for necessary drug concentrate to kill cancer cells.^[40] Therefore, introducing
13
14 stimuli-responsive blocks to endow the electrospun scaffolds with on-demand release capacity
15
16 is a basic requirement in recent studies.^[40, 194] The other concerns related to the insufficient
17
18 cancer cellular uptake of the therapeutics. Due to the susceptibility to multidrug resistance for
19
20 most of the cancer cells and the inherent properties of some therapeutics (such as the negative
21
22 charges of oligonucleotides) that is unfavorable for cancer cell internalization, direct drug
23
24 delivery in a “fiber-to-cell” manner is insufficient for effective cancer treatment.^[195]
25
26
27

28
29 Incorporation of functional nanoparticles into the electrospun scaffolds is a promising strategy
30
31 to solve the aforementioned problems, in view of the well-studied stimuli-responsive capacities
32
33 to physical stimuli and the additional surface for targeting molecules conjugation.^[194] Kim *et*
34
35 *al.*^[196] encapsulated magnetic nanoparticles into DOX-loaded thermo-sensitive polymer N-
36
37 isopropylacrylamide (PNIPAAm) fibers *via* electrospinning to develop a magnetic
38
39 hyperthermia-controlled drug release system (**Figure 15a**). The self-generated heat under the
40
41 alternating magnetic field led to the “on-off” drug release from the fibers. Attributed to the
42
43 synergistic effect of hyperthermia and chemotherapy, 70% of human melanoma cells died
44
45 within 5 min. Ghavaminejad *et al.*^[197] then employed catecholic polymer nanofibers to carry
46
47 and bind the IONPs and bortezomib drugs for synergistic effects from hyperthermia and pH-
48
49 triggered chemotherapy, which reduced the cytotoxicity to healthy tissues/cells.
50
51
52
53
54
55
56
57
58
59

1 Moreover, the formed hierarchical nano-in-nano architectures owned improved
2 biocompatibility and cargo release tunability.^[198] Qiu *et al.*^[199] incorporated the DOX-loaded
3 MSNs into PLLA nanofibers *via* electrospinning, and the obtained PLLA/DOX@MSNs
4 nanofibrous scaffolds showed improved thermal stability than PLLA nanofiber and better anti-
5 proliferation efficacy to Hela cells than the MSNs-free counterparts. An implantable DOX-
6 loaded micelle-in-nanofiber device was developed *via* co-axial electrospinning to treat 4T1
7 murine breast tumor in nude mice (**Figure 15b**).^[121] The folate-conjugated PCL-PEG micelles
8 with DOX were loaded within PVA core region and further shielded by cross-linked gelatin
9 shell. During the degradation of the nanofiber matrix, the micelles were sustainably released
10 from the matrix and accumulated into tumor tissues by interstitial transport and enhanced
11 permeation and retention (EPR) effect, then finally internalized by tumor cells *via* folate
12 receptor-mediated endocytosis. By using this nanodevice, both the side effects of anticancer
13 drugs and the administration frequency can be greatly reduced, while the therapeutic efficacy
14 was maintained.

15 In addition to the conventional nano- or micro- particles, adenoviral (Ad) can also be used to
16 construct nanocomplexes by electrospinning.^[200] Park *et al.*^[200a] demonstrated that Ad can be
17 ionically cross-linked with chitosan-PEG-folate polymer *via* electrospinning. The formed
18 Ad/chitosan-PEG-folate nanocomplexes maintained the biological activity as naked Ad.
19 Moreover, for the folate receptor-expressing KB cells, the transduction efficiency of the Ad-
20 based nanocomplexes was higher than the receptor-negative U343 cells. Besides that, this
21 nanocomplexes also showed reduced immune reaction against Ad.




Figure 15. (a) The magnetic nanoparticles incorporated temperature-responsive poly(NIPAAm-co-HMAAm) nanofibers for DOX release. Reproduced with permission,^[196] Copyright 2013, John Wiley and Sons. (b) Schematic illustrations on the fabrication of the DOX-loaded micelle-in-nanofiber device and the delivery process of these folate-modified DOX-loaded micelles by EPR effect and finally to tumor cells. Reproduced with permission,^[121] Copyright 2015, American Chemical Society.

3.3.2 Biosensors for detection and capture of circulating tumor cell (CTCs)

The detection and capture of cancer cells, especially the CTCs from the patient blood rely on the specific and sensitive recognition of the overexpressed markers on the surface of cancer cells.^[201] However, the low abundance and heterogeneity of the cancer cells in blood environment prevent reliable analyses.^[202] Owing to the tunable morphologies of electrospun fibers that can enhance the local topographic interactions with cancer cells, specific biomarkers modification on fibers-based substrate can amplify the bioassay signals and the antigen-

1 antibody binding with improved accuracy and sensitivity.^[59b, 203] Various proteins on cancer
2 cell surface have been adopted as biomarkers for cancer cell recognition, such as EGFR2 or
3 ErbB2 and carcinoma antigen-125.^[36, 181b, 181d] For instance, Ali *et al.*^[36] fabricated electrospun
4 mesoporous ZnO nanofibers with femtomolar sensitivity for breast cancer diagnostics. After
5 oxygen plasma treatment, the carbon-doped ZnO fibers were available for the conjugation of
6 the antibody of ErbB2 (anti-ErbB2), and they showed high immunoelectrode to ErbB2 with an
7 association constant of $404.8 \text{ kM}^{-1} \text{ s}^{-1}$.
8
9

10 The overexpression of tumor matrix proteins, such as matrix metalloproteinases 9 (MMP-9),
11 can also be used as the biomarker for cancer cell detection. Han *et al.*^[204] prepared a hydrogel-
12 framed polystyrene/poly(styrene-*alt*-maleic anhydride) by electrospinning, and immobilized
13 the fiber with fluorescein isocyanate (FITC)-labeled MMP-9 specific peptides. This enzymatic
14 cleavage-based detection strategy can achieve a detection limit of 10 pM with a response time
15 of 30 min.
16
17

18 The CTCs usually circulated in the blood stream during the tumor metastatic process, which
19 can be regarded as “liquid biopsies” of the primary tumors and the specific mechanism for
20 cancer metastasis.^[201, 205] Zhang *et al.*^[181d] fabricated horizontally packed ultra-long calcinated
21 TiO₂ nanofibers (TiNFs) through electrospun titanium n-butoxide (TBT)/PVP fibers (**Figure**
22 **16a**). Compared with the vertically oriented silicon nanopillars, the horizontally oriented
23 architecture of TiNFs can better mimic the ECM condition, thus leading to further improved
24 cell–substrate interactions. Then the streptavidin was immobilized onto the TiNFs for the
25 follow-up conjugation of the biotinylated epithelial cell adhesion molecule antibody (anti-
26 EpCAM). Based on the enhanced local topographic interactions and the anti-EpCAM/EpCAM
27 biological recognition, this TiNFs showed considerable capture efficiency to the CTCs in both
28 artificial CTC blood samples and whole blood samples from colorectal and gastric cancer
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

patients. To avoid the impurities caused by non-specific captured cells, Hou *et al.*^[206] used a transparent PLGA-nanofiber-embedded nanovelcro chip to replace the non-transparent silicon substrate (**Figure 16b**). Then anti-CD146 antibody was used as melanoma-specific capture agent to conjugate onto the fiber. The nanovelcro chip can efficiently capture the metastatic cells from the blood samples of stage-IV melanoma patients. A Leica LMD7000 microscope equipped with a 355 nm laser microdissection setup was used to cut the PLGA nanofibers for single cell isolation. The obtained cell sample subsequently underwent the whole-genome amplification and specific PCR amplification for the final Sanger g DNA sequencing. This laser microdissection-based single-CMC detection strategy offered an opportunity to investigate the gene-related variations for cancer diagnose.




Figure 16. (a) Schematic illustrations of epithelial-cell adhesion-molecule antibody (anti-EpCAM) modified TiO₂ electrospun nanofibers for cancer cell capture. Reproduced with permission;^[181d] Copyright 2012, John Wiley and Sons. (b) Schematic illustrations of anti-CD146 antibody-grafted PLGA nanofiber-embedded nanovelcro chip for capturing circulating tumor cells. (b1) Fabrication of the nanovelcro substrate. (b2) Chemical conjugation of streptavidin for anchoring of biotinylated anti-CD146. (b3) Schematic illustrations of the mechanism of the nanovelcro CMC chip. (b4) Scheme of the laser microdissection-based single-CMC isolation. Reproduced with permission;^[206] Copyright 2013, John Wiley and Sons.

1 **In summary,** electrospun fibrous scaffolds have evolved from a drug reservoir for sustained
2
3 drug release to a powerful and combinational therapy platform with high compatibility that can
4
5 bridge chemotherapy, thermotherapy and post-surgery tumor treatment. Moreover, new
6
7 therapeutic strategies, such as the tumor guide device, have shown great value for clinical
8
9 translation. However, most of the studies are still restricted on the preclinical level, and the
10
11 systemic investigation and evaluation on the immunogenicity, metabolic cycle and safety of the
12
13 scaffolds are still limited. Besides that, the studies of physical parameters-related patient
14
15 compliance, such as the effects of length, tensile strength, structure and morphology on the
16
17 retention and distribution in the tumor, still require tremendous data support.
18
19
20
21
22
23
24

25 **4. Conclusions and Future Perspectives**

26 **4.1 Conclusions and remarks**

27
28 Electrospun drug delivery vehicles have emerged as one of the essential applications of
29
30 electrospinning in the biomedical field. The high diversity in source materials, drug loading
31
32 techniques and the resultant morphological, physiochemical and biological performances of the
33
34 obtained drug-loaded systems all contributed to the widespread implementations. By choosing
35
36 appropriate polymer matrix, the drugs can be released in seconds, minutes, hours, days or
37
38 months according to diverse requirements in oral/transdermal drug release, tissue regeneration
39
40 or anti-recurrence of tumors. Moreover, by varying the drug loading approaches, loaded drugs
41
42 can be released in rapid, sustained, biphasic or zero-order fashion to meet the timely-varied
43
44 demands during the difference phases of a healing or regeneration process of *in vivo*
45
46 environments. By adding another or more drug delivery vehicles either in particulate
47
48 formulations or another fibrous formulation into the main platform, multifunctional drug
49
50 carriers with time-programed or sequential release of multiple drugs can be created to suit
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 complex *in vivo* conditions. Additionally, pH, temperature, light, electrical or magnetic field
2
3 responsive polymers were employed to further endow the drug carrier systems with controlled
4
5 or multi-staged release features upon exposure to the corresponding stimuli.
6

7
8 Compared to the traditional drug formulations, electrospun fibrous formulations could greatly
9
10 enhance the solubility of water-insoluble drugs due to the highly increased solid dispersion
11
12 induced by high surface-to-volume ratio of electrospun fibers, resulting in faster drug dissolving
13
14 in oral cavity or higher diffusion rate through skin. As an implantable drug-eluting device, apart
15
16 from being the template to support and accommodate the cell proliferation and differentiation,
17
18 electrospun scaffolds can effectively prevent the infection or promisingly enhance the cellular
19
20 metabolism activities through releasing of growth factors or other biomolecules as well. For
21
22 anti-cancer treatment, the possibility to load multiple therapeutics enables the combinational
23
24 therapeutic strategy simultaneously, such as hyperthermic-chemotherapy and photothermal-
25
26 chemotherapy. The electrospun inorganic fibers loaded with biomarkers also represented a new
27
28 strategy to fabricate immunosensor with hypersensitivity for disease diagnosis.
29
30
31
32
33
34
35

36 Overall, electrospun architectures undoubtedly have become multifunctional platforms carrying
37
38 active ingredients to promisingly address the existing medical challenges.
39
40
41
42
43
44

45 4.2 Future perspectives

46
47 Nevertheless, there is still a great gap between the lab validation to clinical trials and then the
48
49 actual commercialization. Currently, no electrospun products have been approved by FDA and
50
51 only few clinical trials have been documented to further testify the function of the designed
52
53 drug delivery platforms.^[207] In a double-blind, randomized and placebo-controlled clinical trial
54
55 of Pathon, a NO releasing PU patch, no sufficient efficacy was observed compared to standard
56
57
58
59
60
61
62
63
64
65

1 treatment.^[208] Apparently, although *in vivo* studies have already been conducted to verify the
2 curing efficacy under the complex *in vivo* environments, the huge difference on size and
3 metabolism systems between human and small animals used *in vivo* study could cause
4 unexpected results during the clinical trials.^[209] Furthermore, both economic burdens and
5 limitations in production rate hindered the large-scale clinical trials in human.^[210] Enormous
6 efforts are still demanding in this aspect.

7
8
9
10
11
12
13
14
15
16 Another limitation for actual commercialization is the low yield of the laboratory
17 electrospinning apparatus. Although high throughput electrospinning systems, such as
18 needleless electrospinning and multi-needle electrospinning are already capable of scaling up
19 the fiber production, the study of drug-loading systems from those equipment were rarely
20 reported.^[211] Several issues restrict the scaling-up and further applications in biomedical fields.
21 For instance, the massive organic solvent evaporation during the high-throughput production
22 could cause severe environmental risk and the solvent residue may compromise the therapeutic
23 effect.^[210] Additionally, quality control and high reproducibility is also challenging in high-
24 throughput electrospinning due to the massive charge accumulation during the long-time
25 process.^[211] The scale-up process may generate drug delivery systems with distinct drug release
26 profiles and physiochemical performances due to the mutual influence among the multi-
27 electrodes, and this long-term charges accumulation. Although some companies have started to
28 work on these problems by designing new spinneret configurations, there is still a long way to
29 go for commercialization of biomedical products.

30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 As a multi-disciplinary subject associated with materials science, pharmaceutical engineering
52 and life science, more dialogues among scientists in diverse disciplines should be opened-up
53 and thus, promote and speed-up the mutual cooperation to further solve the missing puzzles

1 existing in this chain of design – fabrication – laboratory verification – clinical trials –
2
3 commercialization.
4
5
6
7
8

9 **Acknowledgements**

10 Y.D. acknowledges the Orion Research Foundation for financial support. H.A.S. acknowledges
11 financial support from the University of Helsinki Research Funds, the Sigrid Jusélius
12 Foundation (decision no. 4704580), the Helsinki Institute of Life Science, and the European
13 Research Council under the European Union’s Seventh Framework Programme (FP/2007–2013,
14 grant no. 310892).
15
16
17
18
19
20
21
22

23
24 Received: ((will be filled in by the editorial staff))

25
26 Revised: ((will be filled in by the editorial staff))

27
28
29 Published online: ((will be filled in by the editorial staff))
30
31
32
33

34 **References**

- 35
36
37 [1] A. Formhals, *US Patent, 1975504* **1934**.
38
39 [2] a) N. Bhardwaj, S. C. Kundu, *Biotechnol. Adv.* **2010**, 28, 325; b) D. H. Reneker, A. L.
40 Yarin, *Polymer* **2008**, 49, 2387; c) A. Greiner, J. H. Wendorff, *Angew. Chem. Int. Ed.*
41 **2007**, 46, 5670.
42
43
44
45
46 [3] a) T. J. Sill, H. A. von Recum, *Biomaterials* **2008**, 29, 1989; b) X. Hu, S. Liu, G. Zhou, Y.
47 Huang, Z. Xie, X. Jing, *J. Control. Release* **2014**, 185, 12; c) C. Shixuan, B. S. Kumar, B.
48 S. K., L. Xiaoran, X. Jingwei, *Adv. Healthc. Mater.* **2018**, 7, 1701024.
49
50
51
52 [4] a) D. H. Reneker, A. L. Yarin, H. Fong, S. Koombhongse, *J. Appl. Phys.* **2000**, 87, 4531;
53
54 b) D. Li, Y. Xia, *Adv. Mater.* **2004**, 16, 1151.
55
56
57
58
59
60
61
62
63
64
65

- 1 [5] C. B. J. Manuel, V. G. L. Jesús, S. M. Aracely, in *Electrospinning - Material, Techniques,*
2 *and Biomedical Applications*, DOI: 10.5772/65939 (Eds: S. Haider, A. Haider), InTech,
3 Rijeka **2016**, p. Ch. 07.
4
5
6
7
8 [6] S.-F. Chou, D. Carson, K. A. Woodrow, *J. Control. Release* **2015**, 220, 584.
9
10 [7] a) G. R. Williams, N. P. Chatterton, T. Nazir, D.-G. Yu, L.-M. Zhu, C. J. Branford-White,
11 *Ther. Deliv.* **2012**, 3, 515; b) N. Goonoo, A. Bhaw-Luximon, D. Jhurry, *J. Biomed.*
12 *Nanotechnol.* **2014**, 10, 2173.
13
14
15
16
17 [8] F. Ignatious, L. Sun, C.-P. Lee, J. Baldoni, *Pharm. Res.* **2010**, 27, 576.
18
19
20 [9] N. Angelova, D. Hunkeler, *Trends Biotechnol.* **1999**, 17, 409.
21
22 [10] a) X. Li, M. A. Kanjwal, L. Lin, I. S. Chronakis, *Colloids Surf. B Biointerfaces* **2013**, 103,
23 182; b) Z. K. Nagy, K. Nyúl, I. Wagner, K. Molnár, G. Marosi, *Express Polym. Lett.* **2010**,
24 4, 763; c) C. Dott, C. Tyagi, L. K. Tomar, Y. E. Choonara, P. Kumar, L. C. du Toit, V.
25 Pillay, *J. Nanomater.* **2013**, 2013, 19.
26
27
28
29
30
31 [11] a) D.-G. Yu, X.-X. Shen, C. Branford-White, K. White, L.-M. Zhu, S. A. Bligh,
32 *Nanotechnology* **2009**, 20, 055104; b) W. Samprasit, P. Akkaramongkolporn, T.
33 Ngawhirunpat, T. Rojanarata, R. Kaomongkolgit, P. Opanasopit, *Int. J. Pharm.* **2015**, 487,
34 213.
35
36
37
38
39
40
41 [12] H. W. Kwak, H. Woo, I.-C. Kim, K. H. Lee, *RSC Adv.* **2017**, 7, 40411.
42
43 [13] D. C. Aduba, J. A. Hammer, Q. Yuan, W. Andrew Yeudall, G. L. Bowlin, H. Yang, *Acta*
44 *Biomater.* **2013**, 9, 6576.
45
46
47
48 [14] M. Palo, K. Kogermann, I. Laidmäe, A. Meos, M. Preis, J. Heinämäki, N. Sandler, *Mol.*
49 *Pharm.* **2017**, 14, 808.
50
51
52
53 [15] A. Sharma, A. Gupta, G. Rath, A. Goyal, R. Mathur, S. Dhakate, *J. Mater. Chem. B* **2013**,
54 1, 3410.
55
56
57
58
59
60
61
62
63
64
65

- 1 [16] a) X. Wang, D.-G. Yu, X.-Y. Li, S. A. Bligh, G. R. Williams, *Int. J. Pharm.* **2015**, 490,
2 384; b) C. Yang, D. G. Yu, D. Pan, X. K. Liu, X. Wang, S. W. A. Bligh, G. R. Williams,
3 *Acta Biomater.* **2016**, 35, 77.
4
5
6
7
8 [17] a) L. Naves, C. Dhand, L. Almeida, L. Rajamani, S. Ramakrishna, G. Soares, *Prog.*
9 *Biomater.* **2017**, 6, 1; b) J. Song, X. Fan, Q. Shen, *Int. J. Pharm.* **2016**, 501, 245.
10
11
12 [18] a) Y. Liu, A. Nguyen, A. Allen, J. Zoldan, Y. Huang, J. Y. Chen, *Mater. Sci. Eng. C* **2017**,
13 74, 485; b) C. Valenta, B. G. Auner, *Eur. J. Pharm. Biopharm.* **2004**, 58, 279.
14
15
16
17 [19] A. Gencturk, E. Kahraman, S. Güngör, G. Özhan, Y. Özsoy, A. S. Sarac, *Artif. Cells*
18 *Nanomed. Biotechnol.* **2017**, 45, 655.
19
20
21
22 [20] A. C. Mendes, C. Gorzelanny, N. Halter, S. W. Schneider, I. S. Chronakis, *Int. J. Pharm.*
23 **2016**, 510, 48.
24
25
26
27 [21] M. Rasekh, C. Karavasili, Y. L. Soong, N. Bouropoulos, M. Morris, D. Armitage, X. Li,
28 D. G. Fatouros, Z. Ahmad, *Int. J. Pharm.* **2014**, 473, 95.
29
30
31
32 [22] a) T. Ngawhirunpat, P. Opanasopit, T. Rojanarata, P. Akkaramongkolporn, U.
33 Ruktanonchai, P. Supaphol, *Pharm. Dev. Technol.* **2009**, 14, 73; b) K. Kataria, A. Gupta,
34 G. Rath, R. Mathur, S. Dhakate, *Int. J. Pharm.* **2014**, 469, 102.
35
36
37
38 [23] K. Madhaiyan, R. Sridhar, S. Sundarrajan, J. R. Venugopal, S. Ramakrishna, *Int. J. Pharm.*
39 **2013**, 444, 70.
40
41
42
43 [24] Z. Xie, G. Buschle - Diller, *J. Appl. Polym. Sci.* **2010**, 115, 1.
44
45
46
47 [25] Q. Zhang, Y. Li, Z. Y. Lin, K. K. Y. Wong, M. Lin, L. Yildirim, X. Zhao, *Drug Discov.*
48 *Today* **2017**, 22, 1351.
49
50
51
52 [26] K. J. Rambhia, P. X. Ma, *J. Control. Release* **2015**, 219, 119.
53
54
55 [27] M. Sokolsky-Papkov, K. Agashi, A. Olaye, K. Shakesheff, A. J. Domb, *Adv. Drug Deliv.*
56 *Rev.* **2007**, 59, 187.
57
58
59

- 1 [28] a) J. M. Zuidema, M. C. Hyzinski-García, K. Van Vlasselaer, N. W. Zaccor, G. E. Plopper,
2 A. A. Mongin, R. J. Gilbert, *Biomaterials* **2014**, 35, 1439; b) H. J. Cho, S. K. Madhurakkat
3 Perikamana, J. H. Lee, J. Lee, K. M. Lee, C. S. Shin, H. Shin, *ACS Appl. Mater. Interfaces*
4 **2014**, 6, 11225; c) T. Xu, H. Yang, D. Yang, Z. Z. Yu, *ACS Appl. Mater. Interfaces* **2017**,
5 9, 21094.
6
7
8
9
10
11
12 [29] a) A. F. De Faria, F. Perreault, E. Shaulsky, L. H. Arias Chavez, M. Elimelech, *ACS Appl.*
13 *Mater. Interfaces* **2015**, 7, 12751; b) J. Yu, A. R. Lee, W. H. Lin, C. W. Lin, Y. K. Wu,
14 W. B. Tsai, *Tissue Eng. Part A* **2014**, 20, 1896; c) Y. J. Lee, J.-H. Lee, H.-J. Cho, H. K.
15 Kim, T. R. Yoon, H. Shin, *Biomaterials* **2013**, 34, 5059; d) L. Cheng, X. Sun, X. Zhao, L.
16 Wang, J. Yu, G. Pan, B. Li, H. Yang, Y. Zhang, W. Cui, *Biomaterials* **2016**, 83, 169.
17
18
19
20
21
22
23 [30] a) J. Hu, M. P. Prabhakaran, L. Tian, X. Ding, S. Ramakrishna, *RSC Adv.* **2015**, 5, 100256;
24 b) A. V. Bagdadi, M. Safari, P. Dubey, P. Basnett, P. Sofokleous, E. Humphrey, I. Locke,
25 M. Edirisinghe, C. Terracciano, A. R. Boccaccini, J. C. Knowles, S. E. Harding, I. Roy, *J.*
26 *Tissue Eng. Regen. Med.* **2018**, 12, e495.
27
28
29
30
31
32
33 [31] a) J. Xue, M. He, H. Liu, Y. Niu, A. Crawford, P. D. Coates, D. Chen, R. Shi, L. Zhang,
34 *Biomaterials* **2014**, 35, 9395; b) P. Campagnolo, A. J. Gormley, L. W. Chow, A. G. Guex,
35 P. A. Parmar, J. L. Puetzer, J. A. M. Steele, A. Breant, P. Madeddu, M. M. Stevens, *Adv.*
36 *Healthc. Mater.* **2016**, 5, 3046; c) M. B. Taskin, R. Xu, H. Gregersen, J. V. Nygaard, F.
37 Besenbacher, M. Chen, *ACS Appl. Mater. Interfaces* **2016**, 8, 15864.
38
39
40
41
42
43
44 [32] a) Y. Ding, J. A. Roether, A. R. Boccaccini, D. W. Schubert, *Eur. Polym. J.* **2014**, 55, 222;
45 b) Y. Ding, W. Li, T. Müller, D. W. Schubert, A. R. Boccaccini, Q. Yao, J. A. Roether,
46 *ACS Appl. Mater. Interfaces* **2016**, 8, 17098.
47
48
49
50
51
52
53 [33] a) Y. Yao, J. Wang, Y. Cui, R. Xu, Z. Wang, J. Zhang, K. Wang, Y. Li, Q. Zhao, D. Kong,
54 *Acta Biomater.* **2014**, 10, 2739; b) X. Li, M. Li, J. Sun, Y. Zhuang, J. Shi, D. Guan, Y.
55
56
57
58
59
60
61
62
63
64
65

- 1 Chen, J. Dai, *Small* **2016**, 12, 5009; c) X. Yang, J. Yang, L. Wang, B. Ran, Y. Jia, L.
2
3 Zhang, G. Yang, H. Shao, X. Jiang, *ACS Nano* **2017**, 11, 5737.
4
5 [34] a) W. Zhu, S. Liu, J. Zhao, S. Liu, S. Jiang, B. Li, H. Yang, C. Fan, W. Cui, *Acta Biomater.*
6
7 **2014**, 10, 3018; b) X. Luo, M. Chen, Z. Chen, S. Xie, N. He, T. Wang, X. Li, *Acta*
8
9 *Biomater.* **2017**, DOI: 10.1016/j.actbio.2017.12.003; c) P. Dubey, P. Gopinath, *J. Mater.*
10
11 *Chem. B* **2016**, 4, 726.
12
13
14
15 [35] M. Ahmad, C. Pan, Z. Luo, J. Zhu, *J. Phys. Chem. C* **2010**, 114, 9308.
16
17 [36] M. A. Ali, K. Mondal, C. Singh, B. Dhar Malhotra, A. Sharma, *Nanoscale* **2015**, 7, 7234.
18
19 [37] J. S. Jang, S. J. Choi, S. J. Kim, M. Hakim, I. D. Kim, *Adv. Funct. Mater.* **2016**, 26, 4740.
20
21 [38] K. Mondal, A. Sharma, *RSC Adv.* **2016**, 6, 94595.
22
23 [39] Y. Ding, W. Li, A. Correia, Y. Yang, K. Zheng, D. Liu, D. W. Schubert, A. R. Boccaccini,
24
25 H. A. Santos, J. A. Roether, *ACS Appl. Mater. Interfaces* **2018**, DOI:
26
27 10.1021/acsami.8b02656.
28
29
30
31 [40] C. Huang, S. J. Soenen, J. Rejman, B. Lucas, K. Braeckmans, J. Demeester, S. C. De
32
33 Smedt, *Chem. Soc. Rev.* **2011**, 40, 2417.
34
35
36 [41] M. Chen, Y. F. Li, F. Besenbacher, *Adv. Healthc. Mater.* **2014**, 3, 1721.
37
38 [42] S. Thakral, N. K. Thakral, D. K. Majumdar, *Expert Opinion on Drug Delivery* **2013**, 10,
39
40 131.
41
42
43 [43] D. Han, A. J. Steckl, *ACS Appl. Mater. Interfaces* **2017**, 9, 42653.
44
45 [44] M. Jin, D.-G. Yu, C. F. G. C. Geraldes, G. R. Williams, S. W. A. Bligh, *Mol. Pharm.* **2016**,
46
47 13, 2457.
48
49
50 [45] S. Demirci, A. Celebioglu, Z. Aytac, T. Uyar, *Polym. Chem.* **2014**, 5, 2050.
51
52 [46] Y. Guan, Y. Zhang, *Soft Matter* **2011**, 7, 6375.
53
54 [47] L. Li, G. Yang, G. Zhou, Y. Wang, X. Zheng, S. Zhou, *Adv. Healthc. Mater.* **2015**, 4, 1658.
55
56
57
58
59
60
61
62
63
64
65

- 1 [48] J. Hu, H.-Y. Li, G. R. Williams, H.-H. Yang, L. Tao, L.-M. Zhu, *J. Pharm. Sci.* **2016**, 105,
2 1104.
3
4
5 [49] T. Tran, M. Hernandez, D. Patel, J. Wu, *Advances in Materials Science and Engineering*
6 **2015**, 2015, 6.
7
8
9
10 [50] H. Yuan, B. Li, K. Liang, X. Lou, Y. Zhang, *Biomed. Mater.* **2014**, 9, 055001.
11
12
13 [51] Y. F. Li, P. Slemming - Adamsen, J. Wang, J. Song, X. Wang, Y. Yu, M. Dong, C. Chen,
14 F. Besenbacher, M. Chen, *J. Tissue Eng. Regen. Med.* **2017**, 11, 2411.
15
16
17 [52] B. Song, C. Wu, J. Chang, *Regen. Biomater.* **2015**, 2, 229.
18
19
20 [53] D. Han, X. Yu, Q. Chai, N. Ayres, A. J. Steckl, *ACS Appl. Mater. Interfaces* **2017**, 9,
21 11858.
22
23
24 [54] B. Wang, H. Zheng, M.-W. Chang, Z. Ahmad, J.-S. Li, *Colloids Surf. B Biointerfaces*
25 **2016**, 145, 757.
26
27
28 [55] a) X. Zhao, Z. Yuan, L. Yildirimer, J. Zhao, Z. Y. Lin, Z. Cao, G. Pan, W. Cui, *Small* **2015**,
29 11, 4284; b) A. R. K. Sasikala, A. R. Unnithan, Y. H. Yun, C. H. Park, C. S. Kim, *Acta*
30 *Biomater.* **2016**, 31, 122.
31
32
33 [56] H. K. Patra, Y. Sharma, M. M. Islam, M. J. Jafari, N. A. Murugan, H. Kobayashi, A. P. F.
34 Turner, A. Tiwari, *Nanoscale* **2016**, 8, 17213.
35
36
37 [57] Y. Gao, Y. Bach Truong, Y. Zhu, I. Louis Kyratzis, *J. Appl. Polym. Sci.* **2014**, 131, n/a.
38
39
40 [58] a) A. GhavamiNejad, A. Rajan Unnithan, A. Ramachandra Kurup Sasikala, M.
41 Samarikhalaj, R. G. Thomas, Y. Y. Jeong, S. Nasser, P. Murugesan, D. Wu, C. Hee Park,
42 C. S. Kim, *ACS Appl. Mater. Interfaces* **2015**, 7, 12176; b) A. Nasajpour, S. Ansari, C.
43 Rinoldi, A. S. Rad, T. Aghaloo, S. R. Shin, Y. K. Mishra, R. Adelung, W. Swieszkowski,
44 N. Annabi, A. Khademhosseini, A. Moshaverinia, A. Tamayol, *Adv. Funct. Mater.* **2018**,
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 28, 1703437; c) C. H. Woo, Y. C. Choi, J. S. Choi, H. Y. Lee, Y. W. Cho, *Journal of*
2
3 *Biomaterials Science, Polymer Edition* **2015**, 26, 841.
4
5 [59] a) J. A. Kaplan, R. Liu, J. D. Freedman, R. Padera, J. Schwartz, Y. L. Colson, M. W.
6 Grinstaff, *Biomaterials* **2016**, 76, 273; b) S. Chen, S. K. Boda, S. K. Batra, X. Li, J. Xie,
7 *Adv Healthc. Mater.* **2018**, 7, e1701024.
8
9 [60] Z. Zhang, S. Liu, H. Xiong, X. Jing, Z. Xie, X. Chen, Y. Huang, *Acta Biomater.* **2015**, 26,
10 115.
11
12 [61] W. Ji, Y. Sun, F. Yang, J. J. J. P. van den Beucken, M. Fan, Z. Chen, J. A. Jansen, *Pharm.*
13 *Res.* **2011**, 28, 1259.
14
15 [62] H. J. Lai, C. H. Kuan, H. C. Wu, J. C. Tsai, T. M. Chen, D. J. Hsieh, T. W. Wang, *Acta*
16 *Biomater.* **2014**, 10, 4156.
17
18 [63] Z. Man, L. Yin, Z. Shao, X. Zhang, X. Hu, J. Zhu, L. Dai, H. Huang, L. Yuan, C. Zhou,
19 H. Chen, Y. Ao, *Biomaterials* **2014**, 35, 5250.
20
21 [64] J. Hu, L. Tian, M. Prabhakaran, X. Ding, S. Ramakrishna, *Polymers* **2016**, 8, 54.
22
23 [65] L. Li, G. Zhou, Y. Wang, G. Yang, S. Ding, S. Zhou, *Biomaterials* **2015**, 37, 218.
24
25 [66] F. Zhou, X. Jia, Y. Yang, Q. Yang, C. Gao, S. Hu, Y. Zhao, Y. Fan, X. Yuan, *Acta*
26 *Biomater.* **2016**, 43, 303.
27
28 [67] E. N. James, A. M. Delany, L. S. Nair, *Acta Biomater.* **2014**, 10, 3571.
29
30 [68] X. Gu, Y. Matsumura, Y. Tang, S. Roy, R. Hoff, B. Wang, W. R. Wagner, *Biomaterials*
31 **2017**, 133, 132.
32
33 [69] a) A. Townsend-Nicholson, S. N. Jayasinghe, *Biomacromolecules* **2006**, 7, 3364; b) S. N.
34 Jayasinghe, S. Irvine, J. R. McEwan, *Nanomedicine* **2007**, 2, 555; c) S. L. Sampson, L.
35 Saraiva, K. Gustafsson, S. N. Jayasinghe, B. D. Robertson, *Small* **2014**, 10, 78.
36
37 [70] B. Wang, Y. Wang, T. Yin, Q. Yu, *Chem. Eng. Commun.* **2010**, 197, 1315.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [71] a) L. Wistlich, J. Kums, A. Rossi, K. H. Heffels, H. Wajant, J. Groll, *Adv. Funct. Mater.*
2 **2017**, DOI: 10.1002/adfm.201702903; b) Z.-G. Wang, L.-S. Wan, Z.-M. Liu, X.-J. Huang,
3 Z.-K. Xu, *J. Mol. Catal. B: Enzym.* **2009**, 56, 189; c) N. Sachot, M. A. Mateos-Timoneda,
4 J. A. Planell, A. H. Velders, M. Lewandowska, E. Engel, O. Castaño, *Nanoscale* **2015**, 7,
5 15349.
6
7
8
9
10
11
12 [72] X. Qiu, B. L. P. Lee, X. Ning, N. Murthy, N. Dong, S. Li, *Acta Biomater.* **2017**, 51, 138.
13
14 [73] J. Lee, S. K. M. Perikamana, T. Ahmad, M. S. Lee, H. S. Yang, D. G. Kim, K. Kim, B.
15 Kwon, H. Shin, *Tissue Eng. Part A* **2017**, 23, 323.
16
17 [74] R. R. R. Janairo, Y. Zhu, T. Chen, S. Li, *Tissue Eng. Part A* **2014**, 20, 285.
18
19 [75] C. Jia, B. Luo, H. Wang, Y. Bian, X. Li, S. Li, H. Wang, *Adv. Mater.* **2017**, DOI:
20 10.1002/adma.201701154.
21
22 [76] L. Zhu, K. Wang, T. Ma, L. Huang, B. Xia, S. Zhu, Y. Yang, Z. Liu, X. Quan, K. Luo, D.
23 Kong, J. Huang, Z. Luo, *Adv. Healthc. Mater.* **2017**, 6.
24
25 [77] A. Mathew, C. Vaquette, S. Hashimi, I. Rathnayake, F. Huygens, D. W. Hutmacher, S.
26 Ivanovski, *Adv. Healthc. Mater.* **2017**, 6.
27
28 [78] D. W. Song, S. H. Kim, H. H. Kim, K. H. Lee, C. S. Ki, Y. H. Park, *Acta Biomater.* **2016**,
29 39, 146.
30
31 [79] E.-R. Kenawy, G. L. Bowlin, K. Mansfield, J. Layman, D. G. Simpson, E. H. Sanders, G.
32 E. Wnek, *J. Control. Release* **2002**, 81, 57.
33
34 [80] J. Zeng, L. Yang, Q. Liang, X. Zhang, H. Guan, X. Xu, X. Chen, X. Jing, *J. Control.*
35 *Release* **2005**, 105, 43.
36
37 [81] P. Punnakitkashem, D. Truong, J. U. Menon, K. T. Nguyen, Y. Hong, *Acta Biomater.*
38 **2014**, 10, 4618.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [82] A. Y. A. Kaassis, N. Young, N. Sano, H. A. Merchant, D.-G. Yu, N. P. Chatterton, G. R.
2
3 Williams, *J. Mater. Chem. B* **2014**, 2, 1400.
4
5 [83] G. Pan, S. Liu, X. Zhao, J. Zhao, C. Fan, W. Cui, *Biomaterials* **2015**, 53, 202.
6
7 [84] A. J. Meinel, O. Germershaus, T. Luhmann, H. P. Merkle, L. Meinel, *Eur. J. Pharm.*
8
9 *Biopharm.* **2012**, 81, 1.
10
11 [85] Q. Shi, J. Hou, C. Zhao, Z. Xin, J. Jin, C. Li, S. C. Wong, J. Yin, *Nanoscale* **2016**, 8, 2022.
12
13 [86] Z. Zhang, S. Liu, Y. Qi, D. Zhou, Z. Xie, X. Jing, X. Chen, Y. Huang, *J. Control. Release*
14
15 **2016**, 235, 125.
16
17 [87] R. Lakshmanan, P. Kumaraswamy, U. M. Krishnan, S. Sethuraman, *Biomaterials* **2016**,
18
19 97, 176.
20
21 [88] K. Suzuki, H. Tanaka, M. Ebara, K. Uto, H. Matsuoka, S. Nishimoto, K. Okada, T. Murase,
22
23 H. Yoshikawa, *Acta Biomater.* **2017**, 53, 250.
24
25 [89] J. F. C. Viana, J. Carrijo, C. G. Freitas, A. Paul, J. Alcaraz, C. C. Lacorte, L. Migliolo, C.
26
27 A. Andrade, R. Falcão, N. C. Santos, S. Gonçalves, A. J. Otero-González, A.
28
29 Khademhosseini, S. C. Dias, O. L. Franco, *Nanoscale* **2015**, 7, 6238.
30
31 [90] C. Dhand, M. Venkatesh, V. A. Barathi, S. Harini, S. Bairagi, E. Goh Tze Leng, N.
32
33 Muruganandham, K. Z. W. Low, M. H. U. T. Fazil, X. J. Loh, D. K. Srinivasan, S. P. Liu,
34
35 R. W. Beuerman, N. K. Verma, S. Ramakrishna, R. Lakshminarayanan, *Biomaterials*
36
37 **2017**, 138, 153.
38
39 [91] J. A. Roman, I. Reucroft, R. A. Martin, A. Hurtado, H. Q. Mao, *Adv. Healthc. Mater.* **2016**,
40
41 5, 2628.
42
43 [92] C. Zhang, X. Wang, E. Zhang, L. Yang, H. Yuan, W. Tu, H. Zhang, Z. Yin, W. Shen, X.
44
45 Chen, Y. Zhang, H. Ouyang, *Acta Biomater.* **2018**, 66, 141.
46
47 [93] Z. Sun, E. Zussman, A. L. Yarin, J. H. Wendorff, A. Greiner, *Adv. Mater.* **2003**, 15, 1929.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [94] R. Sedghi, A. Shaabani, *Polymer* **2016**, 101, 151.
2
3 [95] H. Jiang, L. Wang, K. Zhu, *J. Control. Release* **2014**, 193, 296.
4
5 [96] L. E. Sperling, K. P. Reis, P. Pranke, J. H. Wendorff, *Drug Discov. Today* **2016**, 21, 1243.
6
7 [97] K. T. Shalumon, G. J. Lai, C. H. Chen, J. P. Chen, *ACS Appl. Mater. Interfaces* **2015**, 7,
8 21170.
9
10 [98] U. Angkawinitwong, S. Awwad, P. T. Khaw, S. Brocchini, G. R. Williams, *Acta Biomater.*
11 **2017**, 64, 126.
12
13 [99] D. G. Yu, X. Y. Li, X. Wang, J. H. Yang, S. W. A. Bligh, G. R. Williams, *ACS Appl.*
14 *Mater. Interfaces* **2015**, 7, 18891.
15
16 [100] G. Z. Yang, J. J. Li, D. G. Yu, M. F. He, J. H. Yang, G. R. Williams, *Acta Biomater.*
17 **2017**, 53, 233.
18
19 [101] J. Zhang, K. Qiu, B. Sun, J. Fang, K. Zhang, H. Ei-Hamshary, S. S. Al-Deyab, X. Mo,
20 *J. Mater. Chem. B* **2014**, 2, 7945.
21
22 [102] D. Han, S. Sherman, S. Filocamo, A. J. Steckl, *Acta Biomater.* **2017**, 53, 242.
23
24 [103] Y. C. Shin, D. M. Shin, E. J. Lee, J. H. Lee, J. E. Kim, S. H. Song, D. Y. Hwang, J. J.
25 Lee, B. Kim, D. Lim, S. H. Hyon, Y. J. Lim, D. W. Han, *Adv. Healthc. Mater.* **2016**, 5,
26 3035.
27
28 [104] C. H. Chen, S. H. Chen, K. T. Shalumon, J. P. Chen, *Acta Biomater.* **2015**, 26, 225.
29
30 [105] E. H. Sanders, R. Kloefkorn, G. L. Bowlin, D. G. Simpson, G. E. Wnek,
31 *Macromolecules* **2003**, 36, 3803.
32
33 [106] a) J. Hu, M. P. Prabhakaran, X. Ding, S. Ramakrishna, *Journal of Biomaterials Science,*
34 *Polymer Edition* **2015**, 26, 57; b) Z. Wang, Y. Qian, L. Li, L. Pan, L. W. Njunge, L. Dong,
35 L. Yang, *J. Biomater. Appl.* **2016**, 30, 686.
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [107] a) T. Briggs, T. L. Arinzeh, *J. Biomed. Mater. Res. A* **2014**, 102, 674; b) N. Nikmaram,
2
3 S. Roohinejad, S. Hashemi, M. Koubaa, F. J. Barba, A. Abbaspourrad, R. Greiner, *RSC*
4
5 *Adv.* **2017**, 7, 28951.
6
7 [108] G. Yazgan, A. M. Popa, R. M. Rossi, K. Maniura-Weber, J. Puigmartí-Luis, D. Crespy,
8
9 G. Fortunato, *Polymer* **2015**, 66, 268.
10
11 [109] A. O. Basar, S. Castro, S. Torres-Giner, J. M. Lagaron, H. Turkoglu Sasmazel, *Mater.*
12
13 *Sci. Eng. C* **2017**, 81, 459.
14
15 [110] N. Cai, C. Han, X. Luo, G. Chen, Q. Dai, F. Yu, *Macromol. Mater. Eng* **2017**, 302,
16
17 1600364.
18
19 [111] W. Li, Y. Ding, R. Rai, J. A. Roether, D. W. Schubert, A. R. Boccaccini, *Mater. Sci.*
20
21 *Eng. C* **2014**, 41, 320.
22
23 [112] X. Xu, X. Zhuang, X. Chen, X. Wang, L. Yang, X. Jing, *Macromol. Rapid Commun.*
24
25 **2006**, 27, 1637.
26
27 [113] H. J. Chung, J. T. Kim, H. J. Kim, H. W. Kyung, P. Katila, J. H. Lee, T. H. Yang, Y. I.
28
29 Yang, S. J. Lee, *J. Control. Release* **2015**, 205, 218.
30
31 [114] X. Zhao, S. Jiang, S. Liu, S. Chen, Z. Y. W. Lin, G. Pan, F. He, F. Li, C. Fan, W. Cui,
32
33 *Biomaterials* **2015**, 61, 61.
34
35 [115] J. Liu, H. Nie, Z. Xu, F. Guo, S. Guo, J. Yin, Y. Wang, C. Zhang, *J. Mater. Chem. B*
36
37 **2015**, 3, 581.
38
39 [116] C. W. He, M. Parowatkin, V. Mailänder, M. Flechtner-Mors, U. Ziener, K. Landfester,
40
41 D. Crespy, *ACS Appl. Mater. Interfaces* **2017**, 9, 3885.
42
43 [117] R. Chandrawati, M. T. J. Olesen, T. C. C. Marini, G. Bisra, A. G. Guex, M. G. de
44
45 Oliveira, A. N. Zelikin, M. M. Stevens, *Adv. Healthc. Mater.* **2017**, 6.
46
47 [118] J. Xue, Y. Niu, M. Gong, R. Shi, D. Chen, L. Zhang, Y. Lvov, *ACS Nano* **2015**, 9, 1600.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [119] N. Monteiro, M. Martins, A. Martins, N. A. Fonseca, J. N. Moreira, R. L. Reis, N. M.
2
3 Neves, *Acta Biomater.* **2015**, 18, 196.
4
5 [120] J. Song, A. Klymov, J. Shao, Y. Zhang, W. Ji, E. Kolwijck, J. A. Jansen, S. C. G.
6
7 Leeuwenburgh, F. Yang, *Adv. Healthc. Mater.* **2017**, 6.
8
9 [121] G. Yang, J. Wang, Y. Wang, L. Li, X. Guo, S. Zhou, *ACS Nano* **2015**, 9, 1161.
10
11 [122] M. S. Kang, J. H. Kim, R. K. Singh, J. H. Jang, H. W. Kim, *Acta Biomater.* **2015**, 16,
12
13 103.
14
15 [123] W. Liu, J. Wei, Y. Wei, Y. Chen, *J. Biomed. Nanotechnol.* **2015**, 11, 428.
16
17 [124] I. Sebe, P. Szabó, B. Kállai-Szabó, R. Zelkó, *Int. J. Pharm.* **2015**, 494, 516.
18
19 [125] H. R. Munj, J. J. Lannutti, D. L. Tomasko, *J. Biomater. Appl.* **2017**, 31, 933.
20
21 [126] a) M. V. Natu, H. C. de Sousa, M. H. Gil, *Int. J. Pharm.* **2010**, 397, 50; b) M. Sadri, A.
22
23 Mohammadi, H. Hosseini, *Nanomedicine Research Journal* **2016**, 1, 112.
24
25 [127] a) S. Nagarajan, L. Soussan, M. Bechelany, C. Teyssier, V. Cavailles, C. Pochat-
26
27 Bohatier, P. Miele, N. Kalkura, J.-M. Janot, S. Balme, *J. Mater. Chem. B* **2016**, 4, 1134;
28
29 b) A. Laha, C. S. Sharma, S. Majumdar, *Mater. Sci. Eng. C* **2017**, 76, 782.
30
31 [128] A. Bohr, Y. Wang, N. Harmankaya, J. J. Water, S. Baldursdottir, K. Almdal, M. Beck-
32
33 Broichsitter, *Eur. J. Pharm. Biopharm.* **2017**, 115, 140.
34
35 [129] T. Potrč, S. Baumgartner, R. Roškar, O. Planinšek, Z. Lavrič, J. Kristl, P. Kocbek,
36
37 *European Journal of Pharmaceutical Sciences* **2015**, 75, 101.
38
39 [130] Y.-N. Jiang, H.-Y. Mo, D.-G. Yu, *Int. J. Pharm.* **2012**, 438, 232.
40
41 [131] T. Pattama, R. Uracha, S. Pitt, *Nanotechnology* **2006**, 17, 2317.
42
43 [132] F. Spano, A. Quarta, C. Martelli, L. Ottobrini, R. M. Rossi, G. Gigli, L. Blasi, *Nanoscale*
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [133] a) A. Akhgari, Z. Shakib, S. Sanati, *Nanomedicine Journal* **2017**, 4, 197; b) M. Rahmani,
2
3 S. Arbabi Bidgoli, S. M. Rezayat, *Nanomedicine Journal* **2017**, 4, 61.
4
5 [134] R. Goyal, L. K. Macri, H. M. Kaplan, J. Kohn, *J. Control. Release* **2016**, 240, 77.
6
7 [135] M. R. Prausnitz, R. Langer, *Nat. Biotechnol.* **2008**, 26, 1261.
8
9 [136] a) Z. Cui, Z. Zheng, L. Lin, J. Si, Q. Wang, X. Peng, W. Chen, *Adv. Polym. Tech.* **2017**,
10
11 0; b) R. Najafi-Taher, M. A. Derakhshan, R. Faridi-Majidi, A. Amani, *RSC Adv.* **2015**, 5,
12
13 50462.
14
15 [137] R. J. Tsai, L. M. Li, J. K. Chen, *N. Engl. J. Med.* **2000**, 343, 86.
16
17 [138] A. Baradaran-Rafii, E. Biazar, S. Heidari-Keshel, *Int. J. Polym. Mate.* **2015**, 64, 879.
18
19 [139] R. S. Bhattarai, A. Das, R. M. Alzhrani, D. Kang, S. B. Bhaduri, S. H. S. Boddu, *Mater.*
20
21 *Sci. Eng. C* **2017**, 77, 895.
22
23 [140] A. Baskakova, S. Awwad, J. Q. Jiménez, H. Gill, O. Novikov, P. T. Khaw, S. Brocchini,
24
25 E. Zhilyakova, G. R. Williams, *Int. J. Pharm.* **2016**, 502, 208.
26
27 [141] L. G. Griffith, G. Naughton, *Science* **2002**, 295, 1009.
28
29 [142] J. Janis, C. Attinger, *Plast. Reconstr. Surg.* **2006**, 117, 12S.
30
31 [143] M. Norouzi, S. M. Boroujeni, N. Omidvarkordshouli, M. Soleimani, *Adv. Healthc.*
32
33 *Mater.* **2015**, 4, 1114.
34
35 [144] a) N. Liao, A. R. Unnithan, M. K. Joshi, A. P. Tiwari, S. T. Hong, C.-H. Park, C. S.
36
37 Kim, *Colloids Surf. A Physicochem. Eng. Asp.* **2015**, 469, 194; b) A. C. Alavarse, F. W.
38
39 de Oliveira Silva, J. T. Colque, V. M. da Silva, T. Prieto, E. C. Venancio, J.-J. Bonvent,
40
41 *Mater. Sci. Eng. C* **2017**, 77, 271.
42
43 [145] a) F. Lv, J. Wang, P. Xu, Y. Han, H. Ma, H. Xu, S. Chen, J. Chang, Q. Ke, M. Liu, Z.
44
45 Yi, C. Wu, *Acta Biomater.* **2017**, 60, 128; b) X. Ren, Y. Han, J. Wang, Y. Jiang, Z. Yi, H.
46
47 Xu, Q. Ke, *Acta Biomater.* **2018**.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- [146] H. Chen, P. Jia, H. Kang, H. Zhang, Y. Liu, P. Yang, Y. Yan, G. Zuo, L. Guo, M. Jiang, J. Qi, Y. Liu, W. Cui, H. A. Santos, L. Deng, *Adv. Healthc. Mater.* **2016**, 5, 907.
- [147] R. H. Dong, Y. X. Jia, C. C. Qin, L. Zhan, X. Yan, L. Cui, Y. Zhou, X. Jiang, Y. Z. Long, *Nanoscale* **2016**, 8, 3482.
- [148] a) B. D. Smith, D. A. Grande, *Nat. Rev. Rheumatol.* **2015**, 11, 213; b) J. L. Madrigal, R. Stilhano, E. A. Silva, *Tissue Eng. Part B Rev.* **2017**, 23, 347.
- [149] a) B. J. Kwee, D. J. Mooney, *Curr. Opin. Biotechnol.* **2017**, 47, 16; b) Q. Chen, J. Jing, H. Qi, I. Ahmed, H. Yang, X. Liu, T. L. Lu, A. R. Boccaccini, *ACS Appl. Mater. Interfaces* **2018**, 10, 11529.
- [150] Y. Yu, S. Hua, M. Yang, Z. Fu, S. Teng, K. Niu, Q. Zhao, C. Yi, *RSC Adv.* **2016**, 6.
- [151] B. Zhang, T. M. Fillion, A. B. Kutikov, J. Song, *Adv. Funct. Mater.* **2017**, 27.
- [152] Y. Liu, G. Zhou, Z. Liu, M. Guo, X. Jiang, M. B. Taskin, Z. Zhang, J. Liu, J. Tang, R. Bai, F. Besenbacher, M. Chen, C. Chen, *Sci. Rep.* **2017**, 7, 8197.
- [153] P. H. M., S. B. N., O. Dinorath, M. H. O., K. D. J., P. K. C., D. N. J., H. D. T. Lynn, *Tissue Eng. Part A* **2017**, 23, 823.
- [154] T. S. Edward, S. N. Navraj, T. Saket, K. Wasim, J. C. Andrew, *Curr. Stem Cell Res. Ther.* **2018**, 13, 1.
- [155] a) M. Younesi, A. Islam, V. Kishore, J. M. Anderson, O. Akkus, *Adv. Funct. Mater.* **2014**, 24, 5762; b) C. Zhang, H. Yuan, H. Liu, X. Chen, P. Lu, T. Zhu, L. Yang, Z. Yin, B. C. Heng, Y. Zhang, H. Ouyang, *Biomaterials* **2015**, 53, 716.
- [156] L. Weng, S. K. Boda, H. Wang, M. J. Teusink, F. D. Shuler, J. Xie, *Adv. Healthc. Mater.* **2018**.
- [157] J. R. McCarthy, *Current cardiovascular imaging reports* **2010**, 3, 42.
- [158] G. Zhao, X. Zhang, T. J. Lu, F. Xu, *Adv. Funct. Mater.* **2015**, 25, 5726.

- 1 [159] H. Parsa, K. Ronaldson, G. Vunjaknovakovic, *Adv. Drug Deliv. Rev.* **2015**, 96, 195.
2
3 [160] a) M. Tallawi, D. C. Zebrowski, R. Rai, J. A. Roether, D. W. Schubert, M. El Fray, F.
4 B. Engel, K. E. Aifantis, A. R. Boccaccini, *Tissue Eng. Part C Methods* **2015**, 21, 585; b)
5 D. Kai, M. P. Prabhakaran, G. Jin, S. Ramakrishna, *J. Biomed. Mater. Res. A* **2011**, 99A,
6 376; c) M. Li, Y. Guo, Y. Wei, A. G. MacDiarmid, P. I. Lelkes, *Biomaterials* **2006**, 27,
7 2705; d) L. Wang, Y. Wu, T. Hu, B. Guo, P. X. Ma, *Acta Biomater.* **2017**, 59, 68.
8
9 [161] a) S. Pascualgil, T. Simónyarza, E. Garbayo, F. Prósper, M. J. Blancoprieto, *Int. J.*
10 *Pharm.* **2017**, 523, 531; b) S. Pascual-Gil, E. Garbayo, P. Díaz-Herráez, F. Prosper, M. J.
11 Blanco-Prieto, *J. Control. Release* **2015**, 203, 23.
12
13 [162] D. Kai, M. P. Prabhakaran, G. Jin, L. Tian, S. Ramakrishna, *J. Tissue Eng. Regen. Med.*
14 **2015**.
15
16 [163] Y. Liu, G. Xu, J. Wei, Q. Wu, X. Li, *Materials Science & Engineering C Materials for*
17 *Biological Applications* **2017**, 81, 500.
18
19 [164] Y. Liu, J. Lu, G. Xu, J. Wei, Z. Zhang, X. Li, *Mater. Sci. Eng. C* **2016**, 69, 865.
20
21 [165] B. Schoen, R. Avrahami, L. Baruch, Y. Efraim, I. Goldfracht, O. Elul, T. Davidov, L.
22 Gepstein, E. Zussman, M. Machluf, *Adv. Funct. Mater.* **2017**, 27.
23
24 [166] a) C. Huang, Y. Ouyang, H. Niu, N. He, Q. Ke, X. Jin, D. Li, J. Fang, W. Liu, C. Fan,
25 T. Lin, *ACS Appl. Mater. Interfaces* **2015**, 7, 7189; b) J. Xue, J. Yang, D. M. O'Connor,
26 C. Zhu, D. Huo, N. M. Boulis, Y. Xia, *ACS Appl. Mater. Interfaces* **2017**, 9, 12299.
27
28 [167] S. Baiguera, C. Del Gaudio, E. Lucatelli, E. Kuevda, M. Boieri, B. Mazzanti, A. Bianco,
29 P. Macchiarini, *Biomaterials* **2014**, 35, 1205.
30
31 [168] Z. Álvarez, O. Castaño, A. A. Castells, M. A. Mateos-Timoneda, J. A. Planell, E. Engel,
32 S. Alcántara, *Biomaterials* **2014**, 35, 4769.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- [169] A. Raspa, A. Marchini, R. Pugliese, M. Mauri, M. Maleki, R. Vasita, F. Gelain, *Nanoscale* **2016**, 8, 253.
- [170] P. Kumar, Y. E. Choonara, G. Modi, D. Naidoo, V. Pillay, *Curr. Pharm. Des.* **2015**, 21, 1517.
- [171] D. R. Nisbet, S. Pattanawong, N. E. Ritchie, W. Shen, D. I. Finkelstein, M. K. Horne, J. S. Forsythe, *J. Neural. Eng.* **2007**, 4, 35.
- [172] C. C. Gertz, M. K. Leach, L. K. Birrell, D. C. Martin, E. L. Feldman, J. M. Corey, *Dev. Neurobiol.* **2010**, 70, 589.
- [173] V. Mahairaki, S. H. Lim, G. T. Christopherson, L. Xu, I. Nasonkin, C. Yu, H. Q. Mao, V. E. Koliatsos, *Tissue Eng. Part A* **2011**, 17, 855.
- [174] A. Hurtado, J. M. Cregg, H. B. Wang, D. F. Wendell, M. Oudega, R. J. Gilbert, J. W. McDonald, *Biomaterials* **2011**, 32, 6068.
- [175] M. Naseri-Nosar, M. Salehi, ShahriarHojjati-Emami, *Int. J. Biol. Macromol.* **2017**, 103.
- [176] K. Zhang, H. Zheng, S. Liang, C. Gao, *Acta Biomater.* **2016**, 37, 131.
- [177] Y. Liu, J. Lu, H. Li, J. Wei, X. Li, *Acta Biomater.* **2015**, 11, 114.
- [178] W. Gong, D. Lei, S. Li, P. Huang, Q. Qi, Y. Sun, Y. Zhang, Z. Wang, Z. You, X. Ye, Q. Zhao, *Biomaterials* **2016**, 76, 359.
- [179] a) M. Zamani, M. P. Prabhakaran, S. Ramakrishna, *Int. J. Nanomedicine* **2013**, 8, 2997; b) S. Lee, G. Jin, J.-H. Jang, *Journal of Biological Engineering* **2014**, 8, 30.
- [180] W. F. Liu, C. S. Chen, *Adv. Drug Deliv. Rev.* **2007**, 59, 1319.
- [181] a) Z. Zha, L. Jiang, Z. Dai, X. Wu, *Appl. Phys. Lett.* **2012**, 101, 193701; b) K. B. Paul, V. Singh, S. R. K. Vanjari, S. G. Singh, *Biosens. Bioelectron.* **2017**, 88, 144; c) M. A. Ali, C. Singh, K. Mondal, S. Srivastava, A. Sharma, B. D. Malhotra, *ACS Appl. Mater. Interfaces* **2016**, 8, 7646; d) N. Zhang, Y. Deng, Q. Tai, B. Cheng, L. Zhao, Q. Shen, R.


- 1 He, L. Hong, W. Liu, S. Guo, K. Liu, H. R. Tseng, B. Xiong, X. Z. Zhao, *Adv. Mater.*
2
3 **2012**, 24, 2756.
4
5 [182] X. Xu, M. C. Farach-Carson, X. Jia, *Biotechnol. Adv.* **2014**, 32, 1256.
6
7 [183] O. Hartman, C. Zhang, E. L. Adams, M. C. Farach-Carson, N. J. Petrelli, B. D. Chase,
8
9 J. F. Rabolt, *Biomaterials* **2010**, 31, 5700.
10
11 [184] T. Amna, N. A. M. Barakat, M. S. Hassan, M.-S. Khil, H. Y. Kim, *Colloids Surf. A*
12
13 *Physicochem. Eng. Asp.* **2013**, 431, 1.
14
15 [185] X. Luo, C. Xie, H. Wang, C. Liu, S. Yan, X. Li, *Int. J. Pharm.* **2012**, 425, 19.
16
17 [186] S. H. Ranganath, C.-H. Wang, *Biomaterials* **2008**, 29, 2996.
18
19 [187] G. Ma, Y. Liu, C. Peng, D. Fang, B. He, J. Nie, *Carbohydr. Polym.* **2011**, 86, 505.
20
21 [188] S. Liu, G. Zhou, D. Liu, Z. Xie, Y. Huang, X. Wang, W. Wu, X. Jing, *J. Mater. Chem.*
22
23 *B* **2013**, 1, 101.
24
25 [189] T. Lu, X. Jing, X. Song, X. Wang, *J. Appl. Polym. Sci.* **2012**, 123, 209.
26
27 [190] X. Xu, X. Chen, Z. Wang, X. Jing, *Eur. J. Pharm. Biopharm.* **2009**, 72, 18.
28
29 [191] C. Achille, S. Sundaresh, B. Chu, M. Hadjiargyrou, *PLoS ONE* **2012**, 7, e52356.
30
31 [192] C. Lei, Y. Cui, L. Zheng, P. Kah-Hoe Chow, C.-H. Wang, *Biomaterials* **2013**, 34, 7483.
32
33 [193] a) R. Ramachandran, V. R. Junnuthula, G. S. Gowd, A. Ashokan, J. Thomas, R.
34
35 Peethambaran, A. Thomas, A. K. K. Unni, D. Panikar, S. V. Nair, M. Koyakutty, *Sci. Rep.*
36
37 **2017**, 7, 43271; b) J. Wei, X. Luo, M. Chen, J. Lu, X. Li, *Acta Biomater.* **2015**, 23, 189.
38
39 [194] S. Mura, J. Nicolas, P. Couvreur, *Nat. Mater.* **2013**, 12, 991.
40
41 [195] a) M. M. Gottesman, T. Fojo, S. E. Bates, *Nat. Rev. Cancer* **2002**, 2, 48; b) J. C.
42
43 Kaczmarek, P. S. Kowalski, D. G. Anderson, *Genom. Med.* **2017**, 9, 60.
44
45 [196] Y. J. Kim, M. Ebara, T. Aoyagi, *Adv. Funct. Mater.* **2013**, 23, 5753.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


- 1 [197] A. Ghavaminejad, A. R. K. Sasikala, A. R. Unnithan, R. G. Thomas, Y. Y. Jeong, M.
2
3 Vatankhah-Varnoosfaderani, F. J. Stadler, C. H. Park, C. S. Kim, *Adv. Funct. Mater.* **2015**,
4
5 25, 2867.
6
7 [198] a) B. Song, C. Wu, J. Chang, *Acta Biomater.* **2012**, 8, 1901; b) F. Zheng, S. Wang, S.
8
9 Wen, M. Shen, M. Zhu, X. Shi, *Biomaterials* **2013**, 34, 1402.
10
11 [199] K. Qiu, C. He, W. Feng, W. Wang, X. Zhou, Z. Yin, L. Chen, H. Wang, X. Mo, *J. Mater.*
12
13 *Chem. B* **2013**, 1, 4601.
14
15 [200] a) Y. Park, E. Kang, O.-J. Kwon, T. Hwang, H. Park, J. M. Lee, J. H. Kim, C.-O. Yun, *J.*
16
17 *Control. Release* **2010**, 148, 75; b) I. C. Liao, S. Chen, J. B. Liu, K. W. Leong, *J. Control.*
18
19 *Release* **2009**, 139, 48.
20
21 [201] S. Maheswaran , L. V. Sequist , S. Nagrath , L. Ulkus , B. Brannigan , C. V. Collura ,
22
23 E. Inserra , S. Diederichs , A. J. Iafrate , D. W. Bell , S. Digumarthy , A. Muzikansky , D.
24
25 Irimia , J. Settleman , R. G. Tompkins , T. J. Lynch , M. Toner , D. A. Haber *N. Engl. J.*
26
27 *Med.* **2008**, 359, 366.
28
29 [202] D. A. Smirnov, D. R. Zweitzig, B. W. Foulk, M. C. Miller, G. V. Doyle, K. J. Pienta, N.
30
31 J. Meropol, L. M. Weiner, S. J. Cohen, J. G. Moreno, M. C. Connelly, L. W. M. M.
32
33 Terstappen, S. M. O'Hara, *Cancer Res.* **2005**, 65, 4993.
34
35 [203] J.-J. Xu, W.-W. Zhao, S. Song, C. Fan, H.-Y. Chen, *Chem. Soc. Rev.* **2014**, 43, 1601.
36
37 [204] S. W. Han, W.-G. Koh, *Anal. Chem.* **2016**, 88, 6247.
38
39 [205] V. Plaks, C. D. Koopman, Z. Werb, *Science* **2013**, 341, 1186.
40
41 [206] S. Hou, L. Zhao, Q. Shen, J. Yu, C. Ng, X. Kong, D. Wu, M. Song, X. Shi, X. Xu, W.-
42
43 H. OuYang, R. He, X.-Z. Zhao, T. Lee, F. C. Brunnicardi, M. A. Garcia, A. Ribas, R. S.
44
45 Lo, H.-R. Tseng, *Angew. Chem. Int. Ed.* **2013**, 52, 3379.
46
47 [207] R. J. Stoddard, A. L. Steger, A. K. Blakney, K. A. Woodrow, *Ther. Deliv.* **2016**, 7, 387.
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

- 1 [208] P. López-Jaramillo, M. Y. Rincón, R. G. García, S. Y. Silva, E. Smith, P.
2
3 Kampeerapappun, C. García, D. J. Smith, M. López, I. D. Vélez, *The American Journal*
4
5 *of Tropical Medicine and Hygiene* **2010**, 83, 97.
6
7
8 [209] S. Soodabeh, M. Azadeh, A. Mohammad, *Current Drug Discovery Technologies* **2015**,
9
10 12, 218.
11
12 [210] P. Luana, C. Andrea, T. Cagri, P. Dario, *Macromol. Mater. Eng* **2013**, 298, 504.
13
14
15 [211] Y. Miao, D. Rui - Hua, Y. Xu, Y. Gui - Feng, Y. Ming - Hao, N. Xin, L. Yun - Ze,
16
17
18 *Macromol. Mater. Eng* **2017**, 302, 1700002.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

The table of contents description

Drug-loaded electrospun architectures are gaining increasing attention in various biomedical applications. By carefully choosing materials/drugs and drug loading techniques, electrospun structures with adjustable topography, tunable porosity, high surface area, and controllable drug release behaviors can be manufactured for biomedical applications, such as simple drug delivery systems, tissue engineering and cancer therapy. The recent progresses are thoroughly overviewed in this review.



Biography


Dr. Yaping Ding is a postdoctoral researcher in Prof. Santos' group at the Faculty of Pharmacy, University of Helsinki. She received her Bachelor's (2008) and Master's (2011) degrees in materials science and engineering from Xi'an Jiaotong University. She then studied polymers and biomaterials under the supervision of Prof. Dirk W. Schubert and Prof. Aldo R. Boccaccini at University of Erlangen-Nuremberg and obtained her Ph.D. degree in 2015. Her research interests are related to drug delivery, biomaterials, and tissue engineering.





Dr. Dongfei Liu earned his Ph.D. in Pharmacy from the University of Helsinki in 2014, under the supervision of Prof. Santos. From 2016 to 2018, he visited Prof. David A. Weitz's group at Harvard University. Currently, he is a principal investigator at the Faculty of Pharmacy and is selected as a HiLIFE Fellow, University of Helsinki. He is well-versed in a variety of fields, such as drug encapsulation, controlled release, microfluidics, biomaterials, and regenerative medicine among others. He is interested in how to engineer biomaterials with ultrahigh mass fraction of therapeutics for controlled drug delivery; he also focuses on the biomedical applications of the fabricated drug delivery systems, such as spinal cord injury therapy, analgesia, and antipsychotic medication.




1
2
3
4
5
6
7
8
9
10
11 Prof. Hélder A. Santos obtained his Doctor of Science in Technology (Chem. Eng.) in 2007
12 from the Helsinki University of Technology, Finland. Currently, he is also the Head of the
13 Division of Pharmaceutical Chemistry and Technology, the Head of the Preclinical Drug
14 Formulation and Analysis Group, and the Head of the Nanomedicines and Biomedical
15 Engineering Group, all at the Faculty of Pharmacy, University of Helsinki, Finland. Prof. Santos
16 is also a HiLIFE Fellow, University of Helsinki. His scientific expertise lies in the development
17 of nanoparticles/nanomedicines for biomedical and healthcare applications, particularly porous
18 silicon nanomaterials for simultaneous controlled drug delivery, diagnostic and treatment of
19 cancer, diabetes, and cardiovascular diseases.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65



Click here to access/download
Supporting Information
copyrights permission.7z





Click here to access/download
Supporting Information
Revised 20180915 clear.docx





Click here to access/download
Production Data
Figure 1.tif



Click here to access/download
Production Data
Figure 2.tif



[Click here to access/download](#)

Production Data
Figure 3.tif









[Click here to access/download](#)

Production Data
Figure 6.tif





[Click here to access/download](#)

Production Data
Figure 7.tif



Click here to access/download
Production Data
Figure 8.tif



Click here to access/download
Production Data
Figure 9.tif



Click here to access/download
Production Data
Figure 10.tif



Click here to access/download
Production Data
Figure 11.tif



Click here to access/download
Production Data
Figure 12.tif






Click here to access/download
Production Data
Figure 14.tif



Click here to access/download
Production Data
Figure 15.tif



Click here to access/download
Production Data
Figure 16.tif



[Click here to access/download](#)

Production Data

Graphic Abstract AFM Ding.tif

